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ABSTRACT 
 
 The mechanisms by which the immune system distinguishes self from non-self are 
essential in providing protection from pathogenic invaders and to prevent autoimmunity. 
Over the last few decades, the discovery of regulatory cells that can suppress specific 
immune responses has introduced a paradigm shift in the study of self versus non-self 
discrimination.  Combined with the discovery of pathogen-associated molecular patterns 
(PAMPS) and damage-associated molecular patters (DAMPS), and their respective Toll 
Like Receptors (TLRs) that trigger an immediate inflammatory response to dangerous 
pathogens or to damaged self, recognizing the pathogens specifically, and maintain self-
tolerance simultaneously, has led to the requirement for re-assessing both the innate and 
the adaptive immune response to either. We have examined the contribution of a highly 
conserved invariant protein, called CD74, to this conundrum.  
 Our experiments involved both activation with TLR agonists or with antigen-
specific receptors to determine the contribution of CD74 in regulating the balance.  TLR 
activation and antigen receptor engagement both result in the proteolysis of CD74 into 
peptides that get loaded into the peptide-binding groove of MHC-II. We reasoned that 
CD74 and its products might provide a molecular contribution that would prevent self-
antigen presentation until a response to specific exogenous antigens is required. While 
we observed that both TLR activation and antigen receptor engagement rapidly result in 
moderate to high levels of cell surface CLIP, respectively, treatment with rapamycin, a 
well-established inhibitor of mTOR that induces autophagy, resulted in loss of cell 
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surface CLIP under either activation stimulus. Furthermore, by using a synthetic peptide 
designed to have a high binding constant for the peptide-binding groove of MHC-II, 
rapamycin rapidly enabled exogenous peptide presentation. The implications of this 
observation in terms of self versus non-self discrimination are supported by our 
experiments using autoimmune prone animals. In these studies antigen receptor 
engagement as well as LPS-induced CLIP expression was reduced by rapamycin 
treatment, enabling exogenous antigenic peptide presentation. These results suggest that 
at least for endosomal TLR activation, preferential expression of endogenous self-
antigens may contribute to the development of autoimmune responses and reciprocally 
to self-tolerance that may prevent an anti-tumoral response. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
B cells  
Over the last few years, B cells have become centrally important with respect to 
their potential contribution(s) to a variety of inflammatory and autoimmune diseases.  B 
cell depletion therapies, using Rituxan™ and/or Rituximab™, have shown promise in 
multiple diseases, including multiple sclerosis, type I diabetes, and rheumatoid arthritis 
amongst others, which were conventionally attributed to the activity of autoreactive T 
cells (Cross et al., 2006; Mok, 2013; Pescovitz et al., 2009).  
In mice, B cells have been characterized as members of two major subsets, B-1 
and B-2 B cells as shown in figure 1. These subcategories of B cells can be distinguished 
based on their anatomical locations and origins, phenotypes and functions (Kantor and 
Herzenberg, 1993).  B2 cells continually arise from bone marrow precursors and are 
continually renewing (Kantor, 1991).  These cells circulate through the blood and 
occupy lymphoid organs, such as lymph nodes and the spleen. B2 cells respond to 
antigens that are both T cell dependent and T cell independent (Martin et al., 2001).  
These cells, once stimulated, are capable of immunoglobulin isotype class switching, are 
known to become long-lived memory cells, and are capable of responding to antigens 
long after the initial exposure to the antigen (Martin and Kearney, 2000). 
B-lymphocytes in humans and mice are classified either into B-1 or B-2 B cells 
based on their ontogeny and anatomical location; B-1 B cells include B-1a, and B-1b 
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cells, while marginal zone (MZ) and Follicular (FO) B cells are considered B-2 lineage 
(Figure 1). B-1 B lymphocytes arise in fetal liver and are self-renewing, while B2 
lymphocytes develop from transitional 2 (T2) B cells from bone marrow precursors with 
continued replacement from the bone morrow (Montecino-Rodriguez and Dorshkind, 
2012; Pillai and Cariappa, 2009).   
MZ B cells produce polyreactive IgM antibodies to remove microorganisms and 
dead cells; they express polyreactive BCR on the surface; CD21 and CD35 complement 
receptors; and CD1d a nonpolymorphic MHC I like molecule (Cerutti et al., 2013). MZ 
B cells develop from transitional B cells and are localized in the marginal sinus of the 
spleen; they recognize T cell independent antigens and T cell dependent protein antigens 
through generation of high-affinity class switched isotypes of antibodies and transport 
complement-bound opsonins onto splenic follicular dendritic cells helping in germinal 
center immune activation (Arnon et al., 2013).  
B-1 and MZ B cells respond to pathogen-associated molecular patterns (PAMPs) 
or endogenous TLR ligands via TLR expression and through BCR, with or without 
antigen recognition (Qian et al., 2006). By initiating a rapid IgM antibody response to 
sustain immunity against infections MZ and B-1 B cells act as innate immune cells until 
the FO B cell derived IgG antibody takes over. FO B cells are part of the adaptive 
immune system and are the most common of all B cells present in the spleen and lymph 
nodes. In the spleen, they develop from transitional B cells and with the help of T cell 
interactions produce IgG a long-lasting antibody important in the humoral immune 
response (Otero et al., 2003). 
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B-1 B cells, often considered “innate” immune cells, are the predominant B cell 
type during fetal and neonatal development (Montecino-Rodriguez and Dorshkind, 
2012).  Throughout life, however, the B-1 B cells can self-renew from stem cell 
precursors and, once formed, B-1 B cells localize to the peritoneal and pleural cavities 
where they produce “natural” IgM and IgA antibodies, which are the front line defense 
against pathogens that often express multiple repeating subunits (Martin et al., 2001; 
Yang et al., 2007). Subsets of B-1 B cells are defined by differential expression of a 
variety of cell surface molecules, including CD5. CD5+IgD-B220+ B-1a B cells produce 
widely reactive IgM antibodies. By contrast CD5-IgD-B220+ B-1b B cells can produce 
long lasting, T cell independent, memory type IgM antibodies to some pathogens 
(Baumgarth, 2011). These B cells express B cell receptors (BCRs) with a repertoire that 
is enriched for cells reactive to highly polymeric antigens, including both microbial and 
self-antigens. Surprisingly, the autoreactive B-1 B cells appear to contribute to tissue 
homeostasis, and potentially self-tolerance (Macpherson and Slack, 2007).   
The repertoire of antigen receptors and the potential for production of “natural 
antibodies” by B-1 B cells result during development, but in the complete absence of 
exposure to foreign antigens (Gronwall et al., 2012).  In fact, autoantibody-producing B-
1 B cells have been shown to undergo a “positive selection” event, where the cells are 
actually selected for their self-reactivity (Choi and Baumgarth, 2008).  This positive 
selection process thus explains the existence of a natural antibody repertoire that 
includes a high frequency of auto-reactive antigen receptors.  The existence of a subset 
of B cells with autoreactive antigen receptors appears to contradict the established 
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paradigm that B cells that are self-reactive are deleted during development to prevent 
autoimmunity.  Emerging data reveal that it may be the self-reactive component of B-1 
B cells that allow these cells to maintain tissue homeostasis as a result of the “self 
recognition” (Ferry et al., 2007). However, this also requires a regulatory mechanism to 
control unwanted activation. We suggest that this function may be provided by selective 
activation of a regulatory category of T cells, known as T regulatory cells (Tregs) (Hsu 
et al., 2015). 
Following activation in the peritoneum or pleural cavities by stimuli including 
LPS, or other Toll-like receptor (TLR) ligands, or some cytokine signals, B-1 B cells are 
rapidly mobilized to the spleen, lymph nodes, and other distal sites from the peritoneum 
(Ha et al., 2006; Itakura et al., 2005). The function of these quickly mobilized cells has 
yet to be fully elucidated, but evidence is mounting that B-1 B cells can serve as both 
effectors, producing large amounts of natural antibodies perhaps aided by their 
interactions with innate-like T cells, natural killer T cells (NKT) and invariant natural 
killer T cells (iNKT) and γδ T cells, and as regulators of adaptive immune responses 
(Campos et al., 2006; Watanabe et al., 2000).  
The B-2 and B-1 subsets of B cells are defined by variable expression of specific 
differentiation antigen, CD5 which is expressed on B-1 B cells but not on B-2 B cells 
(Hardy, 2006). B-1 B cells are one of the main sources of IL-10 production making them 
unlikely candidates for promoting autoimmunity (O'Garra et al., 1992; Popi et al., 2004). 
Reconstitution of B-1 B cells in models of autoimmune diabetes in mice increased 
infiltrating T cells, and there appeared to be limited islet cell destruction (Ryan et al., 
  5 
2010). Protection from diabetes was associated with the entry of Tregs into the pancreas 
following B-1 B cell injection (Ryan et al., 2010). 
 
 
 
 
 
Figure 1: B cell subsets. This picture shows the frequency of B-1 and B-2 B cells in the 
spleen and the surface markers of each cell phenotype (Baumgarth, 2011). Figure 
reproduced with permission from Nature Publishing Group. 
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B cell receptor (BCR) 
B cells are highly efficient at antigen presentation to T cells, followed in 
efficiency by macrophages or dendritic cells. The earliest step in B cell antigen 
processing and presentation requires binding of an antigen to the B cell receptor (BCR) 
and internalization resulting in B cell activation, along with the synthesis and 
transportation of new MHC-II molecules associated with CD74 to the late endosomes. 
The antigen is brought into the endosome with BCR and is exchanged onto the MHC-II 
molecule, which is then transported to the surface for presentation to, and recognition 
by, CD4+ T cells, the initiating event in an adaptive immune response. BCR engagement 
is important for B cell development and clonal selection, for selective removal of non-
specific B cells and for insuring an antigen-specific immune response (Kraus et al., 
2004).  The membrane bound BCR complex is made up of two immunoglobulin heavy 
chains (IgH), and two light chains (IgL) covalently linked to the heavy chains and 
accompanied by Igα and Igβ as signaling components (Niiro and Clark, 2002; Wienands 
and Engels, 2001).  
Once the antigen binds to the BCR, cell proliferation and antigen processing are 
regulated by a downstream signaling cascade (Figure 2), involving a number of activated 
protein tyrosine kinases (PTK). Protein tyrosine kinases SYK and LYN, which are 
activated upon antigen binding initiate signal transduction by phosphorylating the 
activation sites in the cytoplasmic tail of Igα and Igβ. This results in recruitment of 
adapter protein BLNK, which gets activated by its interaction with SYK and helps 
recruit further adaptor proteins BLK and PLCγ2 (Kim et al., 2004). PLCγ2 generates IP3 
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which helps in calcium mobilization from the endoplasmic reticulum and activation of 
nuclear factor of activated T cells (NFAT). In addition, PLCγ2 generates DAG along 
with calcium mobilization leading to induction of PLCβ and activation of NF-κB 
transcription factor, which translocates to the nucleus and initiates transcription of genes 
important for B cell proliferation (Kim et al., 2004). Antigen engagement with BCR also 
results in activation of class I PI3K, which via the Akt pathway inhibits FOXO3 activity, 
leading to B cell proliferation and maintenance (Yusuf et al., 2004).  
The BCR bound antigen undergoes endocytosis and is engulfed by an endosome 
that fuses with a lysosome (forming late endosome), containing acidic hydrolases, which 
help to break down antigens into peptides (Figure 3). The late endosome fuses with the 
MHC-II compartment (MIIC) where antigenic peptides are loaded onto MHC-II 
(Neefjes et al., 2011). The antigen engagement by BCR not only results in intracellular 
organelle rearrangement but also increases the synthesis of MHC-II bound with invariant 
chain (Ii) (CD74) in the ER (Hao and August, 2005). The nonameric MHC-II – Ii protein 
complex translocates to the MIIC where the Ii bound to the MHC-II undergoes 
proteolytic cleavage by some of the cathepsins (Cathepsin S in B cells) leaving behind 
MHC-II associated invariant peptide (CLIP) in the groove of the MHC-II binding 
pocket. Under acidic conditions in the MIIC HLA-DO (H-2O in mice) is inactivated 
allowing HLA-DM (H-2M in mice) to catalyze the replacement of CLIP with the 
antigenic peptide and the MHC-II/antigen complex is finally trafficked to the cell 
surface for CD4+ T cell recognition via its T cell receptor (TCR) (Neefjes et al., 2011).  
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Figure 2: B cell receptor signaling. Schematic presentation of B cell receptor activation 
and down stream signaling (Niiro and Clark, 2002). Figure reproduced with permission 
from Nature Publishing Group. 
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Major histocompatibility complex class-II (MHC-II) and invariant chain (Ii) 
 The major histocompatibility complex class II (MHC-II) presents antigens to 
CD4+ T cells. These glycoprotein complexes are present on the surface of antigen-
presenting cells (APCs) including macrophages, dendritic cells and B cells. The MHC-II 
heterodimer complex is made up of one α and one β chain (Neefjes et al., 2011). Non-
APCs like endothelial cells, intestinal epithelial cells, fibroblasts and glial cells can 
express MHC-II under conditions of inflammation or by exposure to interferon gamma 
(IFN-γ) (Bland, 1988; Geppert and Lipsky, 1985).  The MHC-II encoding genes are 
present on chromosome 6 in humans and on chromosome 17 in mice. In humans, MHC-
II encoding genes are called human leukocyte antigen (HLA) genes and are encoded by 
HLA-DR, -DP, -DQ genes; in mice H-2 genes encode MHC-I genes, H-2K and H-2D, 
and the MHC-II complex I region gene products, I-A and I-E proteins (Shiina et al., 
2009). Class II transactivator (CIITA) is called the “master regulator of MHC-II gene 
expression”, CIITA interacts with various transcription factors at the proximal promoter 
region also known as the locus control region (LCR) of the MHC-II gene and initiates 
mRNA transcription (Lochamy et al., 2007).  
Histone modifications regulate MHC-II transcription as IFN-γ has been shown to 
increase acetylation of H3 and H4 in the HLA-DR promoter region. Histone deacetylase 
inhibitors (HDACs), like trichostatin A (TSA), can also induce MHC-II transcription 
independent of CIITA (Beresford and Boss, 2001; Chou et al., 2005). MHC-II gene 
expression is also regulated at the epigenetic level by suppressing CIITA-PIII promoter 
activity by over expressing the Blimp-1 protein resulting in a lower surface expression of 
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MHC-II (Piskurich et al., 2000). Post-translational modifications are also known to 
regulate MHC-II protein expression; for example, MARCH-1 (membrane associated 
ring-CH-type finger 1) protein acts as an E3 ubiquitin ligase for MHC-II (De Gassart et 
al., 2008). 
MHC-II molecules are assembled in the endoplasmic reticulum (ER) where the 
three MHC-II dimer complexes are assembled on the trimeric invariant chain (Ii), also 
know as CD74 molecule. CD74 is a type II trans-membrane protein. The nonamer 
complex of MHC-II – CD74 moves from ER to the trans-golgi network (TGN) and 
directly to the endocytic system compartment or to the plasma membrane before moving 
into the endocytic compartments (Cresswell, 1994). CD74 acts as a chaperone for MHC-
II enabling its proper folding and transportation from the ER. Post-translational 
phosphorylation of CD74 is essential for the transport of the nonameric complex from 
the ER (Anderson and Roche, 1998). CD74 also prevents binding of self-antigenic 
peptides in the ER by blocking the MHC-II antigen-binding groove through its 
association with CLIP, which sits in the groove of the MHC-II peptide binding pocket 
(Ghosh et al., 1995).  
Movement of the MHC-II – CD74 complex from the ER or cell surface to the 
endocytic compartment for antigen loading is regulated by the “di-leucine like” motifs in 
the N-terminal cytoplasmic tail of the CD74 (Pond et al., 1995). Once the MHC-II – 
CD74 is internalized into the late endosome the CD74 bound to MHC-II undergoes 
various proteolytic cleavages by proteases (such as cathepsin S in B cells) (Figure 3), 
leaving behind only CLIP in the MHC-II peptide binding pocket, which is replaced by 
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the ability of HLD-DM (H-2M in mice) to catalyze its exchange (Sloan et al., 1995). 
Under highly acidic conditions in the late endosome, CLIP in the MHC-II binding 
groove is replaced with exogenous antigenic peptide and the complex is transported to 
the cell surface for antigen presentation to CD4+ T cells. 
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Figure 3: MHC-II and antigen processing and presentation. This figure shows a brief 
overview of the MHC-II – CD74 complex formation and its translocation from the ER, 
processing of CD74, and replacement of CLIP with the antigenic peptide presented on 
the surface of the B cells (Blum et al., 2013).  
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CD74 exists in more than one isoform due to alternative splicing, (Figure 4). In 
mice, CD74 has two forms, p31 (p31Ii) and p41 (p41Ii), which are 215 and 279 amino 
acids long. In humans, CD74 exists in four isoforms p31 (p31Ii), p41 (p41Ii), p35 
(p35Ii) and p43 (p43Ii) with the latter two containing a longer N-terminal (O'Sullivan et 
al., 1987; Shachar et al., 1995). There is no difference in binding affinity of any splice 
variants of CD74 to the MHC-II dimer. In humans, p33Ii is the most common isoform 
accounting for about 80% of the total CD74 in immune cells and the CD74 trimer can 
contain more than one isoform with at least one p35Ii in the trimer complex (Lamb and 
Cresswell, 1992). The p35Ii has an ER retention motif in the N-terminus which acts as a 
quality check to retain the misfolded or improper MHC-II – CD74 complex in ER. The 
p35Ii ER retention motif is phosphorylated and inhibited once it properly associates with 
the MHC-II complex, thereby resulting in transportation of the nonamer complex 
(Anderson et al., 1999). 
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Figure 4: CD74 isoforms in mice and humans. This diagram shows the differences in 
the various isoforms of CD74 both in mice and humans (Schroder, 2016). Figure 
reproduced with permission from Elsevier Publishing Group. 
 
In B cells and other immune cells like macrophages, a small percentage of 
modified CD74 (~ 3 – 5 %) is known to translocate to the cell surface independent of the 
MHC-II complex. This chondroitin sulfate modified CD74 acts as a receptor for 
macrophage migration inhibitory factor (MIF), which binds to the CD74 along with the 
co-receptor CD44 (Figure 5), thus initiating a downstream inflammatory signaling 
pathway that results in activation of NF-κB and CD74-dependent B cell proliferation and 
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survival (Gore et al., 2008). CD74 is important not only for proper MHC-II assembly but 
it also plays an important role in B cell survival, maturation, and proliferation and in 
proper functioning of the adaptive immune system. Loss of CD74 results in reduction in 
MHC-II expression and poor B cell differentiation, and a significant reduction in CD4+ 
T cells in the thymus and periphery, likely due to the lack of a diverse MHC-II peptide 
repertoire required for thymic selection of CD4+ T cells (Bodmer et al., 1994). 
 
 
 
 
 
Figure 5: CD74 mediated downstream signaling. This figures shows the signaling 
transduction downstream of CD74-MIF interaction leading to activation of the 
ERK/MAPK pathway, which plays an important role in cell proliferation and survival 
(Shi et al., 2006). Figure reproduced with permission from Elsevier Publishing Group.  
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Macrophage migration inhibitory factor (MIF) 
 Macrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine, is 
one of the earliest discovered soluble factors that has an important role in regulation of 
innate, adaptive immunity and an inflammatory response. Located on chromosome 22 
(22q11.2) in humans and on chromosome 10 in mice, the molecules are highly 
homologous (Kozak et al., 1995). MIF is conserved across different species, as a 
mammalian homolog of MIF has been detected in fish, insects and bacteria (Jaworski et 
al., 2001; Sato et al., 2003). Initially MIF was thought to be released only by T cells, as 
it was identified as a T cell-derived soluble factor that inhibits migration of 
macrophages, but over the next years, many studies have shown strong evidence that 
MIF expression is ubiquitous. It has a broad tissue distribution, including the immune 
system, with even higher levels of expression in endocrine glands (Baugh and Bucala, 
2002). Innate immune cells when exposed to exotoxins upregulate the expression of 
TLR4 and release MIF along with other cytokines to clear the infection. This release of 
MIF is regulated in an autocrine fashion as it is a positive regulator of TLR4 expression 
(Roger et al., 2001). 
MIF, by binding to CD74 and the chemokine receptors CXCR2 and CXCR4 
plays an important role in inflammation, immune cell proliferation, activation and 
migration (Bernhagen et al., 2007; Leng et al., 2003). MIF binding to CD74 initiates 
activation of extracellular regulated kinases 1/2 (ERK1/2), which in turn activate down 
stream proteins such as PLA2, which is known to inhibit the anti-inflammatory effects of 
steroids (glucocorticoids) and neutralize their immune suppressive activity (Leng et al., 
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2003). MIF has been shown to bind to the chemokine receptors CXCR2 and CXCR4 
alone or along with CD74 and can cause migration of monocytes and T cells resulting in 
progression of atherosclerosis (Bernhagen et al., 2007).  
MIF also plays an important role in B cell migration and maturation as studies 
have shown that MIF binding to CD74 or CD74 along with CXCR4 receptors initiates 
these processes by recruiting surface receptors and activating alternate protein tyrosine 
kinases (Klasen et al., 2014). MIF binding to CD74 and CXCR4 has been shown to 
induce B cell recruitment via activation of ZAP-70 protein tyrosine kinase in B cell 
immune disorders (Klasen et al., 2014). In mature B cells MIF recruits c-Met, a ligand of 
the hepatocyte growth factor receptor (HGFR), to the MIF-CD74/CD44 complex. This 
stimulates the production of hepatocyte growth factor (HGF) and induces activation of 
ETS-2 family transcription factors, which are known to activate anti-apoptotic Bcl-2 
family proteins resulting in cell survival (Gordin et al., 2010).  
MIF is highly expressed in different primary tumors, as it is a negative regulator 
of the tumor suppressor gene p53, an important player in cell cycle regulation and 
induction of apoptosis. MIF inhibits the function of p53 via activation of JAB1 and 
PLA2 proteins. JAB1 inhibits the cell cycle inhibitor KIP1, along with p53, while PLA2 
activates COX2 production which inhibits p53 activity (Conroy et al., 2010). MIF helps 
maintain tumor growth and survival by inducing angiogenesis under hypoxic conditions 
by stabilizing HIF1α expression and by inducing Bcl-2 expression upon binding to 
CD74 (Binsky et al., 2007). 
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Toll-like receptor (TLR) 
 The discovery of TLRs changed the perception of innate immunity from being a 
non-specific unsophisticated subunit of the immune system to being a very important 
and focused player in mounting an initial immune defense.  TLRs help in recognition 
and clearance of pathogens and damaged organelles. Products of pathogen-associated 
molecular patterns (PAMPs) and products of damaged organelles, the danger-associated 
molecular patterns (DAMPs), bind to receptors known as pattern recognition receptors 
(PRR). The Medzhitov and Janeway groups were the earliest investigators to clone 
TLRs; they showed that transfection of hToll chimeric protein into macrophages resulted 
in NF-κB mediated activation of CD80, a co-stimulator of T cells, thus linking innate to 
adaptive immunity (Medzhitov et al., 1997). The protein hToll was later renamed TLR4. 
Since the first cloning of TLR4 there have been 9 more TLRs genes discovered in 
humans and 12 in mice (Kawai and Akira, 2009).  
The N-terminal domain of the TLRs plays an important role in pathogen 
recognition via the leucine rich region (LRR) while the intracellular Toll/IL-1R (ITR) 
domain initiates downstream signaling. TLRs are expressed both at the cell surface and 
intracellularly. TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 are expressed on the cell 
surface, while TLR3, TLR7, TLR8 and TLR9 are expressed in the endosome or in the 
lysosome (Figure 6). TLRs can form homodimers or heterodimers, and recognize 
various microbial products like proteins, lipids, and/or the nucleic acids (dsDNA, 
ssRNA) (Akira et al., 2006; Kawai and Akira, 2009).  
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TLR signaling involves activation of the cytosolic adaptor proteins MyD88 
(Myeloid differentiation primary response gene 88), TIRAP (Toll/interleukin-1 receptor 
domain-containing adapter protein), TRAM (translocating chain-associating membrane 
protein) and TRIF (TIR-domain-containing adapter-inducing interferon-β), which are 
involved in both MyD88-dependent and MyD88-independent pathways. The 
downstream signaling from both pathways results in activation of NF-κB and MAP 
(Mitogen-activated protein) kinase that regulate inflammation. All TLRs except TLR3 
signal through the MyD88-dependent pathway (Kawai and Akira, 2007). In the MyD88-
dependent pathway, TLR interaction with downstream MyD88 activates IRAK4 
(interleukin-1 receptor-associated kinase 4) recruitment, which interacts with and 
activates TRAF6 (TNF receptor associated factor 6), an E3 ligase that forms a complex 
with Ubc13 initiating the ubiquitylation process that activates TAK1 (TGF-β-activated 
kinase 1). TAK1 along with TAB1 (TAK1-binding protein 1), TAB2 (TAK1-binding 
protein 2) and TAB3 (TAK1-binding protein 3) activates the IKK (IκB kinase) complex 
that phosphorylates and degrades IκB (nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor), resulting in NF-κB activation and translocation to the 
nucleus (Chen, 2005; Kawai and Akira, 2007). 
In the MyD88-independent pathway, TRIF plays an important adaptor protein 
role in initiating downstream signal activation. TRIF binds to the cytoplasmic tail of 
TLR3 activating TRAF3 and initiating TBK1 and IKKi complex formation. The TBK1-
IKKi complex phosphorylates IRF3 resulting in its dimerization and translocation to the 
nucleus where it activates IFNβ. The N-terminal region of TRIF induces the NF-κB 
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activation pathway by activating TRAF6 via the RIP1 (receptor-interacting protein 
kinase 1).  
 
 
 
 
 
Figure 6: TLR ligands and TLR signaling. This figure shows various TLR activators 
and their downstream signaling pathways (O'Neill et al., 2013). Figure reproduced with 
permission from Nature Publishing Group. 
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Ubiquitin-proteasome system (UPS) 
 The ubiquitin-proteasome system (UPS) plays an important role in post-
translational regulation of protein quality control in the cells. The UPS system regulates 
ubiquitination, a process of tagging misfolded or improperly assembled proteins with 
multiple ubiquitin (Ub) molecules, which contain 76 amino acids, as 8.5kDa (kilodalton) 
proteins, and targeting them for ATP dependent hydrolyses via the 26S proteasome 
system (Ciechanover and Iwai, 2004). Post-translational modification of proteins by Ub 
molecules occurs on the lysine site of the target protein where the glycine near the 
carboxy terminus of Ub binds to the amino group in lysine on the target protein (Nandi 
et al., 2006). The binding of Ub to the protein targets can regulate their degradation and 
translocation; there are usually multiple Ub molecules binding at Lys-48 of a protein 
resulting in proteasomal degradation, while mono/single Ub binding or classical Lys-63 
binding helps in protein translocation, signal transduction and DNA repair (Weissman, 
2001).  
The Ub tagging of the protein involves a multi-step process before the protein 
can be delivered for proteasomal degradation. The protein-Ub binding is initiated by 
activation of Ub through an ATP-dependent mechanism by enzyme E1. Activated Ub is 
transferred by enzyme E2 from the E1 to the protein substrate that is bound to Ub-
protein ligase family E3. E3 catalyzes the final step in covalent conjugation of Ub to the 
target protein. Successive Ub molecules are added to the previously conjugated Ub on 
the target protein resulting in the polyUb chain that is later recognized by 26S 
proteasome, a multi-catalytic protease complex, for degradation (Mani and Gelmann, 
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2005; Pickart and Eddins, 2004). The 26S proteasome is made up of a 20S catalytic core 
that carries out the degradation activity and a 19S regulatory component at both ends 
that regulates substrate entry into the catalytic core (Zwickl et al., 2001). 
 
Autophagy 
The word autophagy means self-eating. This cellular process was observed about 
50 years ago in rat liver cells in which the mitochondria and other intracellular organs 
were observed to undergo lysosomal degradation (Deter and De Duve, 1967). 
Autophagy is a selective recycling pathway for clearing up damaged intracellular 
organelles and protein aggregates, where the intracellular components are delivered to 
lysosomes to enable cell survival during starvation conditions. Cells use autophagy to 
breakdown lipids, carbohydrates and amino acids to synthesize new proteins or to meet 
the energy demands for normal cellular function.   
There is a basal level of autophagy in every cell that is upregulated when the 
cells are stressed. The stress stimulus can be either nutrient deprivation, exposure to 
radiation, and/or oxidative stress. All these conditions result in a systemic imbalance in 
cells and the autophagy process can help restore intracellular homeostasis (Mizushima et 
al., 2008). The similarity between autophagy and proteasomal degradation ends at 
clearing of misfolded proteins. Autophagy not only clears long-lived proteins, but it also 
is involved in the clearance of intracellular organelles, while proteasomal degradation 
targets removal of short-lived proteins (Wu et al., 2010). In the last 10 years many 
groups have shown that there is an important crosstalk between these two degradation 
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pathways as it was shown that inhibition of UPS resulted in a compensatory upregulation 
of the autophagy process to clear the ubiquitinated proteins and inhibition of autophagy 
enhanced the proteasomal degradation pathway (Wang et al., 2013; Wu et al., 2010; Wu 
et al., 2008). 
Based on the mode of delivery of cargo, in the lysosomes there are three types of 
autophagy processes that have been identified (Figure 7): microautophagy, chaperone-
mediated autophagy (CMA), and macroautophagy. Microautophagy is not involved in 
the cell survival process as it plays a role in maintaining cell size and membrane 
integrity under starvation conditions. This process is the simplest of all of the autophagic 
processes as proteins are directly transported to the lysosome for degradation without the 
requirement of any adapter proteins or membrane vacuoles, as occurs in CMA and 
macroautophagy. Like macroautophagy, rapamycin can induce this process, thus 
indicating that the target of rapamycin (TOR) regulates the microautophagy process 
(Uttenweiler et al., 2007).  
CMA is a very selective process and is involved in the delivery of soluble 
cytosolic proteins only. It does not move cellular organelles for degradation nor does it 
require any special membrane structures for delivery of the substrate proteins. The CMA 
process involves binding of chaperone proteins to the target substrate containing a 
conserved peptide motif KFERQ, which is based on this amino acid sequence being 
present in over 25% of the cytosolic proteins (Dice, 1990). Heat shock protein family 
member Hsc70 acts as the chaperone in CMA by binding to the substrate protein at the 
KFERQ amino acid sequence site and transporting them to the lysosome (Chiang et al., 
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1989; Dice, 1990). Substrate protein unfolding, which is an essential step for the 
translocation into the lysosome, is a poorly understood process. LAMP-2A, a single-
span membrane protein on the lysosome acts as receptor protein in the CMA process. 
The substrate binds to the monomeric LAMP-2A resulting in formation of a multimeric 
complex that aids in translocation of the substrate protein into the lysosome for 
degradation (Cuervo and Dice, 1996). 
Macroautophagy is the most widely studied of all the autophagic processes and it 
is the most complex process of the three types of autophagy. Macroautophagy can 
deliver not only proteins but also cellular organelles like damaged mitochondria, ER, 
and Golgi to the lysosome for acidic hydrolysis. The process of macroautophagy 
involves engulfment of the substrate protein/organelle into a double membrane vesicle, 
called the autophagosome, which moves along the microtubules to fuse with the 
lysosome for delivery of the cargo for degradation (Gallagher and Chan, 2013). Akt 
regulates macroautophagy via the mammalian target of rapamycin (mTOR) protein. 
Under nutrient replete conditions Akt is active and protects the mTOR phosphorylation 
by downregulating TSC1/2, a negative regulator of mTOR. By contrast under stress 
conditions Akt is inactivated, leading to AMPK activation, which stabilizes the TSC1/2 
complex resulting in the phosphorylation and inactivation of mTOR as well as causing 
“induction of autophagy ” (Huang and Manning, 2008, 2009).  
The process of macroautophagy involves sequestration (Figure 8) of proteins and 
damaged organelles that includes initiation, elongation and closure of the 
autophagosome, as well as transportation and degradation of the autophagosome 
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(Gallagher and Chan, 2013). The process of formation of the double layered isolation 
membrane, called the autophagosome, is an essential step in the initiation of the 
autophagic process. The isolation membrane can originate from anywhere in the cell 
though there is strong evidence that it is assembled near the ER (Fujita et al., 2008). 
There are over 30 autophagy-associated genes (atg) that are involved in the process of 
macroautophagy, with the ULK1 complex initiating the process (Mizushima et al., 
2011).  
The process of autophagosome formation and the targeting of the substrate to the 
autophagosome occur simultaneously. Processing of the target substrate for the 
autophagosome involves ubiquitination of the substrate by several E3 ligases and 
binding of these modified substrates to the adaptor proteins, like NBR1 and 
SQSTM1/p62, which translocate them to the autophagosome. The mature 
autophagosome, containing the substrate, moves along the microtubules, fuses with the 
lysosome, and the autophagosome/lysosome contents undergo acidic hydrolysis and 
recycled molecules are exported back into the cytosol via the lysosomal efflux 
transporter. These recycled molecules are used for biosynthesis of new organelles or for 
cell metabolism (Johansen and Lamark, 2011; Kuang et al., 2013; Yang et al., 2006). 
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Figure 7: Types of autophagy. This figure shows different types of the autophagy 
processes and the adaptor proteins and secondary structures that are involved in the 
delivery of the substrate to the lysosome (Tasset and Cuervo, 2016). Figure reproduced 
with permission from John Wiley and Sons Publishers. 
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Figure 8: Molecular pathway of macroautophagy. This figure shows the most important 
autophagy-associated proteins that are involved in the macroautophagy process along 
with the physiological importance of macroautophagy (Levine and Kroemer, 2008). 
Figure reproduced with permission from Elsevier Publishing Group. 
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Macroautophagy and CMA are important player in many human diseases and in 
immunity. Cancer cells utilize the autophagy process for their survival, as many studies 
of tumors have shown a positive association between autophagy and multi-drug 
resistance to chemotherapeutic agents (Sui et al., 2013). Autophagy has a complex 
interaction with the inflammasomes in cells, as studies have shown that inhibition of 
autophagy by chemical inhibitors or gene silencing results in reduced pro-inflammatory 
cytokine production by macrophages (Harris et al., 2011). The autophagy process is a 
major regulator of chronic inflammation, as studies of Crohn’s disease have shown that 
mutations in autophagy protein ATG16L an important regulator of autophagy genes, 
results in diminished bacterial clearance by autophagy (xenophagy) leading to bacterial 
overload and inflammation (Murthy et al., 2014).  
Autophagy is indispensible in B and T cell development and function. Atg5-/-
mice have shown a significant reduction in the peritoneal B-1a B cell population and 
impaired pre- and mature B2 cell development (Miller et al., 2008). Atg5-/- thymus graft 
transplantation into a recipient mouse results in a significant decrease in the negative 
selection of T cells in these animals indicating that autophagy is essential for negative 
selection of T cells (Klein et al., 2010). One third of all the antigens presented by B cells 
in the MHC-II are intracellular antigens and autophagy plays an important role in the 
processing and presentation of intracellular proteins, especially mitochondrial proteins, 
to T cells. While autophagy is essential for intracellular antigen presentation it is not a 
significant player in membrane-bound antigen presentation (Aichinger et al., 2013; 
Dengjel et al., 2005).  
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Rationale 
The aim of this work was to determine the mechanism(s) by which the 
processing of CD74 and subsequent cell surface expression of CLIP in the groove of 
MHC-II on activated B cells contributes to, or regulates, endogenous versus exogenous 
antigenic peptide presentation by B cells. We also explore the contribution of CD74 
processing to B cell activation, survival, proliferation, expansion, and inflammation. We 
propose that cell surface CLIP expression is differentially regulated by macroautophagy 
and CMA in B cells. The central hypothesis of this proposal is that macroautophagy and 
CMA are important in differentiating “self versus non-self” antigen presentation and that 
these processes regulate the expansion and survival of distinct B cell subsets. The 
rationale for our hypothesis is that if we determine how autophagic processes affect the 
ability of B cells to present endogenous versus exogenous antigenic peptides, this 
knowledge can help improve therapeutic approaches in the treatment of a wide range of 
diseases, including autoimmune diseases, cardiovascular disease, chronic inflammatory 
diseases, and cancers in which B cell presentation of endogenous versus exogenous 
antigens may be major contributors. 
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CHAPTER II 
MATERIALS AND METHODS 
 
Reagents 
 RPMI 1640 cell culture media, heat inactivated fetal bovine serum (FBS), 
200mM L-glutamine, 1M HEPES buffer, ACK lysis buffer, gentamicin sulfate, 100mM 
sodium pyruvate, phosphate buffered saline (PBS), LIVE/DEAD® Fixable Aqua Dead 
Cell Stain Kit and CellTrace™ Violet Cell Proliferation Kit were purchased from 
Thermo Fisher Scientific Inc. (Waltham, MA); penicillin – streptomycin (concentration 
of 10,000 units/mL - 10 mg/mL, respectively) was purchased from Sigma–Aldrich Inc. 
(St. Louis, MO); and 40µm nylon cell strainers were purchased from Fisher Scientific 
Inc. (Hampton, NH). 
 TLR4 agonist lipopolysaccharide (LPS) was purchased from Sigma – Aldrich 
Inc., TLR9 ligand CpG – oligodeoxynucleotide CpG – ODN 2006 (CpG) was purchased 
from InvivoGen Inc. (San Diego, CA), F(ab’)2 fragment of anti-mouse IgM was 
purchased from Jackson ImmunoResearch Laboratories Inc.(West Grove, PA), and 
interleukin-4 (IL-4) was purchased from Affymetrix Inc. (Santa Clara, CA). 
 
Small molecular inhibitors and antibodies 
 For in vitro treatment of splenocytes we purchased rapamycin (Sirolimus) and 
bortezomib (PS-341) from Selleckchem Inc. (Houston, TX), and Hydroxychloroquine 
sulfate (HCQ) from Sigma – Aldrich Inc. Cathepsin Inhibitor 1, an inhibitor of 
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cathepsins was purchased from ApexBio Inc. (Houston, TX), brefeldin A (BFA) a fungal 
metabolite was purchased from Sigma–Aldrich Inc., and the MIF inhibitor ISO-1 was 
purchased from TOCRIS Bioscience Inc. (Bristol, UK). For B and T cell (including 
CD4+ and CD8+ T cells) staining for flow cytometry, Pacific Blue™-conjugated 
hamster anti-mouse CD3e, APC-Cy™7-conjugated rat anti-mouse CD19 (Clone 1D3), 
and PE-Cy™7™-conjugated rat anti-mouse CD8 antibodies were purchased from BD 
Biosciences Inc. (San Jose, CA), while APC-conjugated anti-mouse MHC Class II (I-
A/I-E) antibody was purchased from Affymetrix Inc. (Santa Clara, CA). PerCP/Cy5.5-
conjugated rat anti-mouse CD4 was purchased from BioLegend Inc. (San Diego, CA), 
and FITC-conjugated mouse anti-mouse CLIP (clone 15G4), which can only detect the 
CLIP in the binding pocket of MHC-II I-Ab (of H-2b haplotype) mice, was purchased 
from Santa Cruz Biotechnology Inc. (Dallas, TX). Dr. Richard Bucala from Yale 
University, School of Medicine (New Haven, CT) generously provided MIF-098, a 
potent inhibitor of MIF. 
 For staining of the B-1 B cells and B-2 B cells from the peritoneal cavity the 
following antibodies were purchased for B-1/B-2 B cell panel staining.  APC-Cy™7-
conjugated rat anti-mouse CD19 and PE-conjugated rat anti-mouse CD45R/B220 were 
purchased from BD Biosciences Inc., while PE-Cy™7-conjugated rat anti-mouse CD5 
and Pacific Blue™-conjugated rat anti-mouse IgD were purchased from BioLegend Inc.
 For competitive peptide binding studies, the target biotinylated peptide APi1702 
with higher binding affinity for the MHC alleles than CLIP, was synthesized using an 
algorithm that detects peptides with high binding affinity for MHC-II (Newell et al., 
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2010). The sequence of the biotinylated peptide, which is a 9-mer of SGG GAN SGF 
RIM AVL ASG GQY, was synthesized by Elim Biopharma Inc. (Hayward, CA) 
 
Mice 
C57BL/6 mice and B6.lpr mice, with a spontaneous mutation (Faslpr) making 
them prone to autoimmune diseases, were purchased from Jackson Laboratory Inc. (Bar 
Harbor, ME). CD74-deficient (CD74def) mice were generously provided by Dr. Scott 
Zamvil (University of California, San Francisco, in San Francisco CA), All animals were 
housed in the Baylor Scott and White Hospital vivarium facility according to the 
Institutional Animal Care and Use Committee guidelines.  
 
Splenocyte isolation 
 Mice were anaesthetized using isoflurane, followed by cervical dislocation and 
dissection of spleens from the animals. Spleens were collected, washed in PBS 
containing 3% FBS (final vol/vol %) (FBS/PBS) and passed through 40µm nylon cell 
strainers to make single cell suspensions. The red blood cells were lysed by incubating 
the cell pellet in ACK buffer for 6 minutes at room temperature (25oC) in the dark and 
washed twice with FBS/PBS to remove traces of ACK buffer. The splenocytes were 
collected as a pellet and left on ice.  
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Peritoneal cavity lymphocyte isolation 
 Mice were anesthetized using isoflurane and then euthanized in a CO2 chamber. 
Five mL of ice cold FBS/PBS was injected into the peritoneum of the animal and after 
90 seconds the solution was collected using a Pasteur pipette. The collected FBS/PBS 
from the animal contains a mixture of B-1 and B-2 B cells and other immune cells. Since 
we euthanize the animals in a CO2 chamber, there is very little contamination with red 
blood cells and so there is no need to do an ACK lysis step. Collected cells were washed 
once and were prepared for experimental use. 
 
Splenocyte activation and treatment 
 Isolated splenocytes were plated at a concentration of 1 x 106 cells/mL in a 
Corning® Costar® 24-well flat bottom cell culture plate in RPMI 1640 cell culture 
medium supplemented with heat inactivated FBS at 5% final concentration (vol/vol %), 
2mM L-glutamine, 10mM HEPES, 1mM sodium pyruvate, 100 units of penicillin and 50 
milligrams of streptomycin. Splenocytes were activated with TLR4 agonist LPS, TLR9 
agonist CpG or F(ab’)2 fragment of anti-mouse IgM + IL-4 (anti-IgM + IL-4) along with 
various chemical activators and inhibitors of autophagy and proteasomal degradation. 
The cells were incubated in a water jacketed CO2 incubator (Thermo Fisher Scientific 
Inc., Waltham, MA) with 5% CO2 concentration and 95% humidity. 
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Proliferation assay 
 The B cell proliferation assay was performed using CellTrace™ Violet Cell 
Proliferation Kit. The basic principle of this proliferation assay is dye dilution and 
reduction in fluorescence with each generation (i.e. division). For this experiment, we 
prepared a 5 mM stock solution of CellTrace™ Violet Cell Proliferation dye in dimethyl 
sulfoxide (DMSO). Isolated splenocytes from the mice were cleared of red blood cells 
by incubating with the ACK buffer followed by washing with FBS/PBS solution. For 
staining, a pre-calculated number of splenocytes were resuspended in prewarmed PBS. 
The dye was added for a final concentration of 5µM concentration per 1 million cells per 
mL and cells were incubated at 37oC for 20 minutes in the dark. Cells were washed 
twice with FBS/PBS to quench unreacted dye. The stained cells were plated in a 24-well 
plate and stimulated with TLR agonist with and without a macroautophagy activator. 
 
Competitive peptide binding studies 
 For the in vitro competitive peptide binding studies, the APi1702 was dissolved 
in DMSO at a concentration of 5mg/mL as a stock. For the assay, splenocytes isolated 
from the C57BL/6 mouse spleens were plated at a concentration of 1 million cells per 
well of a 24-well plate in 1 mL RPMI1640 growth medium supplemented with 5% FBS 
containing all the standard amino acids. The cells were then activated with the TLR 
stimulants (CpG or LPS) or treated for BCR activation (with anti-IgM + IL-4) and were 
treated either with rapamycin or HCQ at a concentration of 10µM along with APi1702 
peptide at a final concentration of 5µg/mL. After 48 hours of incubation in the CO2 
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incubator, the cells were washed and first stained for the surface markers CD19, CD3, 
CLIP, and MHC-II utilizing antibodies conjugated with different fluorochromes and 
incubated on ice for 20 minutes. Cells were washed twice with FBS/PBS and later 
stained with streptavidin to stain for the surface expression of APi1702. A negative 
control was included in experiment where few non-treated but activated wells were 
stained to get the background signal of the biotin – avidin system. Once the cells were 
analyzed, the geometrical mean fluorescence intensities of CLIP and APi1702 were 
normalized and the ratio of APi1702 to CLIP was calculated for each sample and 
plotted. 
 
Cell surface staining and flow cytometry 
 B and T cell subsets in the cultured splenocytes were evaluated by surface 
staining of the splenocytes with Pacific Blue™ rat anti-mouse CD3e, APC-Cy™7 rat 
anti-mouse CD19, PE-Cy™7 rat anti-mouse CD8, APC rat anti-mouse MHC Class II (I-
A/I-E), PerCP/Cy5.5 rat anti-mouse CD4, and FITC mouse anti-mouse CLIP (15G4) 
along with LIVE/DEAD® Fixable Aqua Dead Cell Stain. The cells were analyzed on a 
Becton Dickson FACSCanto II flow cytometer (BD Biosciences Inc., San Jose, CA), 
consisting of a 3 laser 10 parameter system with FACSDiva software (BD Biosciences 
Inc., San Jose, CA). The flow data was analyzed using FlowJo® software (FlowJo, LLC, 
Ashland, OR)  
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Statistical analysis 
 The acquired data from the FlowJo® software was saved in Microsoft Excel 
(Redmond, WA) files. The data plotting was done and statistical significance was 
analyzed using GraphPad Prism 6 software (La Jolla, CA).  
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CHAPTER III 
RESULTS 
 
Differential cell surface CLIP expression in response to TLR agonists and BCR 
engagement   
To characterize the extent of CLIP expression resulting from various stimulators 
of B cell activation, we conducted in vitro experiments using the splenocytes from 
C57BL/6 mice. Splenocytes stimulated with TLR9 agonist CpG-ODN 2006 (CpG) at a 
concentration of 5µg/mL, TLR4 ligand LPS at a concentration of 5µg/mL, or F (ab)’2 
fragment of anti-mouse IgM + IL-4 (anti-IgM + IL-4) at a concentration of 10µg/ml and 
5ng/mL, respectively. We used a fragment of the antibody against the receptor instead of 
intact antibody against the BCR because intact antibody binding results in B cell 
inactivation and cell death (Phee et al., 2001). After 48 hours of in vitro culture, the 
cultured splenocytes were harvested and stained with fluorochromes-conjugated CD19, 
CD3, CLIP, and MHC-II antibodies.  
We observed a statistically significant increase in the number of CLIP positive 
(CLIP+) B cells with both LPS and CpG stimulation as well as with anti-IgM + IL-4 
stimulation (Figure 9A; n = 3; P < 0.05). The geometric mean of fluorescence intensity 
(MFI), used as an indicator of the level of expression of the molecule per B cell 
increased with statistical significance when compared to the level of expression on 
resting B cells (figure 9B; n= 3; P<0.05). The highest level of CLIP per B cell resulted 
from stimulation with anti-IgM + IL-4 CLIP. The geometric mean fluorescence intensity 
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of MHC-II per B cell (MHC-II (MFI)) also increased with CpG activation and anti-IgM 
+ IL-4 stimulation (P<0.05), while LPS did not change the expression of MHC-II 
(Figure 9C; n= 3;). The frequency of B cells increased with all B cell stimulators when 
compared to resting B cells (Figure 9D; n= 3; P<0.05)  
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Figure 9: CLIP expression with TLR agonists and BCR activation. Panel A shows that 
the frequency of CLIP+ B cells increase with the TLR4 and TLR 9 agonists, LPS and 
CpG, respectively, and with anti-IgM + IL-4 (n = 3; P<0.05). Panel B shows a 
significant increase in geometric mean fluorescence intensity (MFI) of CLIP per B cell 
when activated with different ligands of TLR and anti-IgM + IL-4 (n = 3; P<0.05), as 
indicated. Panel C shows geometric mean fluorescence intensity (MFI) of MHC-II 
surface expression per B cell stimulated with CpG (n = 3; P<0.05), LPS (n = 3) and anti-
IgM + IL-4 for 48 hours (n = 3; P<0.05). Panel D shows the change in number of B cells 
resulting from treatment with LPS, CpG or anti-IgM + IL-4 (n = 3; P<0.05). Statistical 
significance was evaluated by one-way ANOVA using GraphPad Prism.  
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Rapamycin inhibits B cell proliferation and CLIP expression on B cells and reduces 
B cell viability and CLIP expression 
Autophagy is a process that helps degrade cellular material and organelles under 
conditions of stress or nutrient deprivation. Rapamycin is an established inhibitor of 
mTOR that promotes autophagy. To address the possibility that autophagy contributes to 
the increase in the level of CLIP or the frequency of CLIP+ B cells resulting from TLR 
or antigen receptor engagement, we studied the effect of rapamycin, using in vitro 
experiments, on B lymphocytes from the spleen of C57BL/6 mice. Splenocytes isolated 
from the C57BL/6 were stimulated with either CpG at a concentration of 5µg/mL or with 
LPS at a concentration of 5µg/mL or with anti-IgM + IL-4 at concentrations of 10µg/ml 
and 5ng/mL respectively, in a 24 well plate with and without rapamycin at a 
concentration of 10µM for 48 hours.  
We observed that in vitro rapamycin treatment reduced the frequency of total B 
cells in all the three stimulation groups (Figure 10A; n = 3; P < 0.05). This drop in the 
population of B cells was significant. Rapamycin treatment reduced the number of viable 
CLIP+ B cells in the TLR4 and TLR9 agonist activated groups as well as in the BCR 
activation group (Figure 10B; n = 3; P < 0.05). Next we looked at the level of expression 
of CLIP per cell (MFI) and observed a significant reduction in all the groups (Figure 
10C; n = 3; P < 0.05). Because the CLIP antibody used in our staining can only detect 
the CLIP in the peptide-binding groove of MHC-II we wanted to see if rapamycin-
induced reduction in CLIP was the result of reduced expression of MHC-II. In fact, 
rapamycin significantly increased the level of expression of MHC-II (MFI) (Figure 10D; 
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P < 0.05) in all treatment groups, indicating that induction of autophagy can reduce the 
expression of CLIP on B cells, while maintaining or even increasing the level of 
expression of MHC-II. 
 
 
CpG LPS anti-IgM + iL-4
0
20
40
60
80
100
48Hour Activation + Treatment
CL
IP+
 B
-C
ell
s (
% 
of 
Liv
e C
ell
s)
C57BL/6 Spleen
Control Rapamycin
P < 0.05 P < 0.05 P < 0.05
B
CpG LPS anti-IgM + iL-4
0
20
40
60
80
100
B-
Ce
lls
(%
 of
 Li
ve
 ce
lls
)
C57BL/6 
Control Rapamycin
P < 0.05
P < 0.05 P < 0.05
A
CpG LPS anti-IgM + iL-4
0
2000
4000
6000
8000
10000
48Hour Activation + Treatment
CL
IP(
MF
I)
C57BL/6 Spleen
Control Rapamycin
P < 0.05 P < 0.05
P < 0.05
C
CpG LPS anti-IgM + iL-4
0
20000
40000
60000
80000
48Hour Activation + Treatment
MH
CI
I (M
FI)
C57BL/6 Spleen
Control Rapamycin
P < 0.05P < 0.05
P < 0.05
D
 
 
 
Figure 10: Rapamycin-induced inhibition of CLIP expression. Panel A shows that 
rapamycin treatment results in increases in B cell death in LPS, CpG, and anti-IgM + IL-
4 activated groups when treated in vitro at a concentration of 10µM (n = 3; P < 0.05). 
Panel B shows that rapamycin strongly suppresses the increase in CLIP+ B cell 
expression (n = 3; P < 0.05) in all the treatment groups. Panel C shows that rapamycin 
reduces the level of CLIP (MFI) per cell in all the activation groups (n = 3; P < 0.05). 
Panel D shows that rapamycin significantly increases the level of expression of MHC-II 
in the cells in all the three stimulant groups (n = 3; P < 0.05). P values were calculated 
using Student’s t-test on GraphPad Prism. 
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Rapamycin inhibits B cell proliferation 
We observed that rapamycin inhibits the B cell proliferation in both the CpG-
activated splenocyte population and the anti-IgM + IL-4 activated group (Figure 11A, 
Figure 11B; n = 3; P < 0.05). We analyzed the number of B cell divisions that the 
splenocytes had undergone. Under the “no rapamycin” conditions the splenocytes 
underwent five doubling generations in the 48-hour time period. When treated with 
rapamycin the cells underwent fewer divisions in both CpG activated (Figure 11C; n = 3; 
#: P <0.05) and anti-IgM + IL-4 stimulated groups (Figure 11D; n = 3; #: P <0.05), 
indicating that rapamycin inhibits the proliferation of CLIP+ B cells. 
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Figure 11: Rapamycin inhibits B cell proliferation. Panel A shows the reduction in the 
total percentage of B-cell proliferation with rapamycin when the cells were treated with 
CpG (n = 3; P < 0.05). Panel B shows treatment of IgM + IL-4 activated splenocytes 
with rapamycin inhibits B cell proliferation and the reduction is significant (n = 3; P < 
0.05). Panel C shows that rapamycin treated B cells under conditions of TLR9 (CpG) 
activation undergo cell cycle arrest in the second generation (P < 0.05). Panel D shows 
the rapamycin-mediated inhibition of B cell proliferation in anti-IgM + IL-4 stimulated 
splenocytes (n = 3; P < 0.05). P values were calculated using Student’s t-test on 
GraphPad Prism. 
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Hydroxychloroquine, as an autophagy inhibitor, increases cell surface CLIP 
expression  
Our data has shown that rapamycin reduces the level of CLIP (MFI) and the 
frequency of CLIP+ B cells. Thus, we predicted that hydroxychloroquine (HCQ), 
reported to inhibit macroautophagy, would increase the level of expression of CLIP 
(MFI) and the frequency of CLIP+ B cells. As predicted, the levels of expression of cell 
surface CLIP (MFI) increased when macroautophagy was inhibited via HCQ treatment 
(Figure 12C; n = 3; P < 0.05). After 48 hours of in vitro culture, with 10µM HCQ, we 
observed that splenocytes from C57BL/6 cultured in the presence of HCQ and 
stimulated with LPS, or with anti-IgM+IL-4, showed no reduction in the frequency of 
CLIP+ B cells (Figure 12B; n = 3), while the frequency was reduced following CpG 
activation in the presence of HCQ (Figure 12B; n = 3; P < 0.05). The TLR9 receptor is 
present on the endosomal/lysosomal membrane and we postulated that the reduction in 
the CLIP+ B cells with HCQ in CpG activated cells could be due to HCQ-induced 
neutralization of the endosome/lysosomal compartment.  
HCQ treatment reduced B cell viability in CpG-activated splenocytes and in anti-
IgM + IL-4 (Figure 12A; P < 0.05; n = 3), but not in LPS-activated splenocytes (Figure 
12A; n = 3; P > 0.05). HCQ did not induce changes in the surface expression of MHC-II 
in LPS activated or anti-IgM+IL-4 stimulated cells. However HCQ increased the surface 
expression of MHC-II in CpG-activated B cells (Figure 12D; P < 0.05; n = 3). These 
data suggest that CpG-induced increases in the number of CLIP+ B cells depends upon 
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the ability of CpG to signal via TLR9 and thus may be a function of 
lysosomal/endosomal pH. 
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Figure 12: HCQ induces CLIP expression on B cells. In Panel A HCQ reduces the 
viability of B cells in CpG activated and anti-IgM+IL-4 activated splenocytes (P < 0.05) 
(n = 3). Panel B shows that HCQ only inhibited CLIP+ B cells in CpG activated 
splenocytes but not in the other two stimulations (P < 0.05) (n = 3).  Panel C shows that 
HCQ significantly increased the expression of CLIP in MHC-II under all three 
conditions of stimulation (P < 0.05) (n=3). Panel D shows that HCQ treatment of CpG 
activated splenocytes resulted in higher expression of MHC-II on B cells (P < 0.05), 
while there was no change in MHC-II expression following LPS or anti-IgM+IL-4 
activation  (n = 3). P values were calculated using Student’s t-test on GraphPad Prism. 
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Rapamycin alters B-1/B-2 B cell ratio 
 Because our previous results have shown that rapamycin reduces CLIP (MFI) on 
the surface of the B cells, we sought to determine if the effect of rapamycin was 
equivalent or different on sub-populations of B cells, i.e. on the B-1 versus the B-2 B 
cell subsets. The peritoneum has a relatively high frequency of B-1 B cells when 
compared to spleen. We isolated the peritoneal cavity-derived lymphocytes (PerC) from 
C57BL/6 mice and activated the cells in vitro in a 24 well plate with CpG at a 
concentration of 5µg/mL with or without rapamycin (10µM) and cultured the cells for 48 
hours.  
 Rapamycin treatment reduced the frequency of IgD-B220+CD19+ B-1 B cells 
subsets (Figure 13A; n = 3; P < 0.05) from the peritoneum, resulting in an increase in the 
ratio of IgD+B220-CD19+ B-2 to IgD-B220+CD19+ B-1 B cells (Figure 13B; n = 3; P < 
0.05). We explored the possibility that rapamycin might selectively affect either B-1a or 
B-1b subsets of B-1 B cells. We also observed that rapamycin reduced the frequency of 
both B-1 CD5+IgD-B220+CD19+ B-1a and CD5-IgD-B220+CD19+ B-1b B cell subsets 
(Figure 13C, 13D; n = 3; P < 0.05). These results suggest that autophagy, via inhibition 
of mTOR, selects for an increase in the relative number of B-2 B cells, increasing the 
likelihood for T-dependent B cell activation of B-2 cells and the production of T-
dependent B cell antibody production. 
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Figure 13: Rapamycin alters the B-1/B-2 B cell ratio. Peritoneal cavity cells were 
stimulated with CpG and cultured in vitro for 48 hours with and without 10µM 
rapamycin, Panel A shows that CpG stimulation activated IgD-B220+CD19+ B-1 B cells 
(n = 3; P<0.05) and rapamycin treatment reduced the percentage of viable IgD-
B220+CD19+ B-1 B cells (n = 3; P<0.05). Panel B also shows that the IgD+B220-CD19+ 
B-2 cell frequency was increased. The percentage of B-1 B cells upon exposure to CpG 
and rapamycin was reduced and we observed an increase in the total number of B-2 B-
cells (n = 3; P<0.05). Panel C shows that the CD5+IgD-B220+CD19+ B-1 B cell subset, 
known as B-1a B cells, which act as natural IgM producing cells are reduced in the 
presence of rapamycin (n=3; P<0.05). Panel D shows that CD5-IgD-B220+CD19+ B-1 
cells known as B-1b B cells and which act as memory B cells, are also reduced in 
response to rapamycin treatment (n=3; P<0.05). P values were calculated using 
Student’s t-test on GraphPad Prism. 
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Rapamycin increases, and HCQ reduces, antigenic peptide loading 
Because our data shows that rapamycin causes a reduction in the surface 
expression of CLIP, we hypothesized that loss of CLIP should be compensated for by an 
increase in antigenic peptide presentation by the B cells. We used a biotinylated peptide 
that has a higher binding affinity for the peptide-binding groove of MHC-II than for 
CLIP. The peptide APi1702 was reconstituted in DMSO and was added at a final 
concentration of 5µg/mL to splenocytes activated with CpG, LPS, or anti-IgM + IL-4, 
along with either 10µM of rapamycin or 10µM of HCQ.  
The cells were stained 48 hours later, using a two-step method.  First, the cells 
were stained with fluorochrome-conjugated antibodies to the cell surface markers CD19, 
CD3, CLIP, or MHC-II. Then streptavidin was added to detect the surface bound 
biotinylated APi1702 in the groove of MHC-II. The normalized ratio of the geometric 
mean fluorescence intensities of Api1702 to CLIP is plotted for rapamycin treatment and 
HCQ, giving an estimate for the ratio of Api1702 to CLIP in the groove of MHC-II. We 
found that the APi1702/CLIP ratio went up with rapamycin treatment, compared to 
control, while it went down in response to HCQ treatment, as was the case for all the 
activators (Figure 14; n = 3). This indicated that macroautophagy aids in the replacement 
of CLIP with antigenic peptide. Rapamycin increased the APi1702/CLIP ratio by about 
two-fold in CpG, LPS, and anti-IgM + IL-4 stimulations, while HCQ reduced the 
APi1702/CLIP MFI in all the three activation groups (Figure 14A, 14B, 14C; n = 3; P < 
0.05). 
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Figure 14: Macroautophagy regulates antigenic peptide loading. Panel A shows that 
with CpG stimulation and the ratio of synthetic peptide (APi1702) to CLIP in the groove 
of MHC-II went up with rapamycin treatment (P <0.05; n = 3), while the ratio is reduced 
with HCQ treatment (P <0.05; n = 3). Panel B shows that under conditions of LPS 
activation, the APi1702/CLIP ratio increased in B cells with rapamycin treatment (P 
<0.05; n = 3), while the ratio was reduced significantly with HCQ (P <0.05; n = 3). 
Panel C shows that, analogous to CpG and LPS, treatment with anti-IgM + IL-4 along 
with rapamycin or HCQ differentially regulates the ratio of APi1702/CLIP. Treatment 
with rapamycin significantly increased the ratio (P <0.05; n = 3), while treatment with 
HCQ significantly reduced the APi1702/CLIP ratio (P <0.05; n = 3). Statistical 
significance was evaluated by one-way ANOVA using GraphPad Prism.  
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Chaperone mediated autophagy (CMA) regulates the expression of CLIP per B cell 
in vitro 
 Based on our preliminary data, and on data from the laboratory of Janis Blum, 
and colleagues (Perez et al., 2016), we see that TLR activation increases the level of the 
lysosomal protein LAMP-2C and inhibits MHC Class II Presentation of cytoplasmic 
antigens by disrupting CMA. We addressed the possibility that stimulation of B cells 
with antigen receptor engagement (i.e., anti-IgM+IL-4) would stimulate CMA resulting 
in increased cell surface CLIP expression, while TLR activation that promotes at least 
some degree or some aspects of macroautophagy, would result in lower levels of cell 
surface CLIP than anti-IgM + IL-4 treated cells that utilize CMA via LAMP2A 
induction.   
We performed experiments to determine if activation of CMA affects CLIP 
expression and frequency of CLIP+ B cells under two conditions of activation. For these 
experiments, we isolated splenocytes from C57BL/6 mice and activated them with either 
CpG at a concentration of 5µg/mL, LPS at a concentration of 5µg/mL or anti-IgM + IL-4 
at a concentrations of 10 µg/ml and 5 ng/mL respectively, for 24 hours with and without 
140 µM 6-amino-nicotinamide (6-AN), a well-established inhibitor of 6-
phosphogluconate dehydrogenase, the NADP+-dependent enzyme that activates 
CMA.We noted a significant increase in the frequency of B cells (Figure 15A; n = 3; P < 
0.05) with no change in CLIP+ B cell frequency (Figure 15B; n = 3), in CpG, LPS and 
anti-IgM + IL-4 activated splenocytes, when treated with 6-AN.Treatment with 6-AN 
resulted in reduction of cell surface CLIP (MFI) on B cells in all three activation groups 
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(Figure 15C; n = 3; P < 0.05). While 6-AN treatment did not affect the surface level of 
MHC-II expression on B cells in the CpG-activated group, it significantly reduced 
MHC-II (MFI) on the B cell surface in LPS and anti-IgM + IL-4 activated groups 
(Figure 15D; n = 3). These data suggest that even though CMA reduces the surface CLIP 
expression, it might not contribute to antigenic peptide presentation, because it also 
reduces the expression of MHC-II, at least in TLR4 activation and BCR engagement. 
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Figure 15: 6-AN reduces the surface expression of CLIP on B cells. Panel A shows that, 
in 24 hours of in vitro stimulation with CpG, LPS or anti-IgM + IL-4 activation along 
with 6-AN treatment, significantly increases the frequency of B cells (n = 3; P < 0.05). 
Panel B shows that 6-AN treatment concomitant with CpG or LPS or anti-IgM + IL-4 
activation for 24 hours in vitro does not affect the frequency of CLIP+ B cells (n = 3). 
Panel C shows that 6-AN strongly suppresses cell surface CLIP expression on B cells. 
Panel D shows that the effect of 6-AN on surface expression of MHC-II on the B cells. 
With the exception of the CpG-activated group, 6-AN significantly reduced MHC-II 
(MFI) in both LPS-activated and anti-IgM + IL-4 activated splenocytes (n = 3; P < 0.05). 
P values were calculated using Student’s t-test on GraphPad Prism. 
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CD74 deficient (CD74def) mice have an altered immune cell profile 
 CLIP is the proteolytic product of CD74, also known as invariant chain (Ii).  
CLIP is loaded in the peptide-binding groove of MHC-II until a peptide replaces it. We 
performed some of the same studies described above using CD74 deficient (CD74def) 
mice.  These mice were generated on a C57BL/6 background.  We first analyzed the B 
and T cell profiles of CD74def mice and observed that the immune cell profile in these 
animals is different than in C57BL/6 wild type (BL6 WT). We stained for B cells, MHC-
II expression on B cells, CD4+ T cells, and CD8+ T cells from the spleen of the CD74def 
mice and compared their frequency to that of BL6 WT mice (Figure 16; n = 3).  
CD74def mice have significantly fewer B cells (Figure 16A; n = 3; P < 0.05).  
Because CD74 plays an important role in MHC-II assembly, the absence of CD74 likely 
explains the significantly lower expression of MHC-II on B cells in the CD74def mice 
compared to WT (Figure 16B; n = 3; P < 0.05). This result is consistent with reports by 
other groups (Bikoff et al., 1993). Lower levels of MHC-II inhibit the expansion of 
CD4+ T cells in the thymus.  Our results show that CD74def animals have significantly 
fewer CD4+ T cells in spleen than the BL6 WT (Figure 16C; n = 3; P < 0.05), but have a 
higher frequency of CD8+ T cells compared to the WT animals (Figure 16D; n = 3; P < 
0.05). 
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Figure 16: CD74def mice B and T cell profiles in the spleen. Panel A shows that the 
frequency of B cells in the spleen of the CD74def mice was significantly lower than in 
BL6 WT mice (n = 3; P < 0.05). Panel B shows surface MHC-II expression on B cells in 
CD74def mice was significantly lower than in the BL6 WT mice (n = 3; P < 0.05). Panel 
C shows that lack of MHC-II repertoire potentially resulted in fewer CD4+ T cells in 
CD74def than in the BL6 WT mice (n = 3; P < 0.05). Panel D shows there was a higher 
frequency of CD8+ T cells in the CD74def mice than in the BL6 WT mice (n = 3; P < 
0.05). P values were calculated using Student’s t-test on GraphPad Prism. 
 
We stained the lymphocytes from the peritoneal cavity of the CD74def animals.  
The peritoneal cavity of these animals had a lower frequency of B-1 and B-2 B cells in 
their peritoneum (Figure 17; n = 3). The frequency of B-1 (Figure 17A; n = 3; P < 0.05), 
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B-2 (Figure 17B; n = 3; P < 0.05), and B-1a (Figure 17C; n = 3; P < 0.05) B cells was 
low compared to the BL6 WT mice, while the B-1b B cell (Figure 17D; P < 0.05) 
frequency was higher. 
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Figure 17: CD74def mice B-1 and B-2 B cell subset profile. Panel A shows that the 
frequency of B-1 B cells in the peritoneum of the CD74def mice was significantly lower 
than in BL6 WT mice (n = 3; P < 0.05). Panel B shows that frequency of B-2 B cells in 
CD74def mice was lower than in the BL6 WT mice (n = 3; P < 0.05). Panel C shows that 
BL6 WT mice had a higher frequency of the B-1a B cell subset than CD74def animals (n 
= 3; P < 0.05). Panel D shows that there was a higher frequency of B-1b B cells in the 
CD74def mice than in the BL6 WT mice (n = 3; P < 0.05). Student’s t-test was used to 
evaluate significance with GraphPad Prism. 
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CD74def splenocyte response to HCQ, rapamycin, and 6-AN 
 Splenocytes isolated from CD74def mice were activated in vitro with CpG, LPS, 
or anti-IgM + IL-4 for 48 hours, along with either 10µM HCQ, 10µM rapamcyin (Rapa), 
or with 6-AN at a concentration of 140µM. As CD74def B cells do not express CLIP, we 
stained for MHC-II expression on the B cells and found that compared to naïve 
splenocytes, fewer B cells survive with the TLR stimulants or with anti-IgM + IL-4 
activation (Figure 18; #: P < 0.05; n = 3). The effect of rapamycin varied with 
stimulation, as rapamycin upregulated MHC-II surface expression on B cells after CpG 
stimulation, without affecting the B cell frequency (Figure 18A; #: P < 0.05; n = 3) and 
reduced MHC-II expression on B cells along with B cell frequency during anti-IgM + 
IL-4 stimulation (Figure 18C; #: P < 0.05; n = 3). While LPS/TLR4 activation along 
with rapamycin had no effect on MHC-II surface expression, this treatment caused a 
strong reduction in the frequency of activated B cells (Figure 18B; #: P < 0.05; n = 3).  
HCQ did not affect the B cell frequency, while it reduced B cell surface MHC-II 
expression during CpG activation (Figure 18A; #: P < 0.05; n = 3). MHC-II (MFI) was 
upregulated in LPS-activated splenocytes that were treated with HCQ (Figure 18B; #: P 
< 0.05; n = 3) with no change in the frequency of CLIP+ B cells. 6-AN had a strong 
inhibitory effect on the CpG-activated B cell levels of cell surface MHC-II  (Figure 18A; 
#: P < 0.05; n = 3) with no effect on B cell frequency. In contrast, LPS in the presence of 
6-AN reduced the B cell frequency and increased MHC-II surface expression (Figure 
18B; #: P < 0.05; n = 3) in LPS-activated splenocytes. In anti-IgM + IL-4 activated 
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splenocytes 6-AN reduced MHC-II surface expression along with the frequency of B 
cells (Figure 18C; #: P < 0.05; n = 3). 
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Figure 18: The response of CD74def splenocytes to HCQ, Rapamycin, or 6-AN in vitro. 
Panel A shows that rapamycin (Rapa) or 6-AN increased the B cell surface expression of 
MHC-II, while HCQ reduced the MHC-II expression (n = 3; #: P < 0.05) in CpG 
activated splenocytes from CD74def animals.  Neither rapamycin nor 6-AN had any 
affect on B cell frequency. Panel B shows that in LPS-activated splenocytes, rapamycin 
reduced the B cell frequency (n = 3; #: P < 0.05) with no effect on MHC-II (MFI), while 
6-AN reduced the B cell frequency and significantly increased the level of MHC-II 
(MFI) (n = 3; #: P < 0.05). HCQ increased the surface expression of MHC-II on the 
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CD74def B cells without affecting the frequency of the B cells. Panel C shows that in 
anti-IgM + IL-4 activated cells, induction of macroautophagy and CMA results in B cell 
loss and a reduction in the level of cell surface of MHC-II on the B cells from CD74def 
splenocytes (n = 3; #: P < 0.05), while inhibition of macroautophagy had no effect on the 
B cell frequency nor on the level of MHC-II (MFI) on the B cells. Statistical significance 
was calculated by one-way ANOVA method using GraphPad Prism. 
 
Bortezomib (PS-341) reduces CLIP expression in B cells 
 PS-341 is an inhibitor of proteasomal degradation.  To determine if cell surface 
CLIP results from proteasomal degradation of CD74, C57BL/6 splenocytes were 
activated for 24 hours in vitro with CpG at a concentration of 5 µg/mL, with LPS at a 
concentration of 5 µg/mL, or anti-IgM + IL-4 at concentrations of 10 µg/ml and 5 
ng/mL, respectively, in a 24 well plate for 24 hours with or without 100 nM PS-341.  
We observed that the treatment with PS-341 significantly reduced the frequency 
of B cells (Figure 19A; n = 3; P < 0.05), CLIP+ B cells (Figure 19B; n = 3; P < 0.05), 
and cell surface CLIP expression on B cells (Figure 19C; n = 3; P < 0.05). While PS-341 
also significantly reduced the mean surface MHC-II fluorescence intensity on the B cells 
in LPS activated and anti-IgM + IL-4 activated groups, it upregulated the B cell surface 
expression of MHC-II (MFI) in CpG activated cells (Figure 19D; n = 3; P < 0.05). 
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Figure 19: Proteasomal inhibitor reduces CLIP per B cell. Figure A shows that in vitro 
treatment of CpG, LPS and anti-IgM + IL-4 activated splenocytes with PS-341 
significantly reduced the frequency of B cells (n = 3; P <0.05). Figure B shows that PS-
341 blocked the expansion of CLIP+ B cells in all three activation groups (n = 3; P < 
0.05). Figure C shows that in all three activation groups, PS-341 treatment suppressed 
the CLIP surface expression on the B cells (n = 3; P < 0.05). Figure D shows that the 
effect of PS-341 on the MHC-II surface expression on B cells is stimulation-dependent, 
as CpG-activated groups showed a significant increase in MHC-II (MFI) on B cells 
while in LPS and anti-IgM + IL-4 activated groups, PS-341 reduced the B cell surface 
expression of MHC-II (n = 3; P < 0.05). P values were calculated using Student’s t-test 
on GraphPad Prism. 
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Cathepsin inhibitor 1 regulation of surface CLIP 
Cathepsins are cysteine proteases that play an important lysosomal role in 
proteolytic cleavage of antigenic peptides and of the MHC-II-bound CD74. Cathepsin 
cleavage of CD74 is known to generate the CLIP peptide that gets loaded into the MHC-
II peptide binding groove, until it is replaced by antigenic peptides. We explored the 
possibility that blocking cathepsin activity will affect CLIP expression. For this 
experiment, we isolated splenocytes, activated them with either CpG or anti-IgM + IL-4 
and treated them for 48 hours with cathepsin inhibitor 1 (Cystatin-1, 10µM), which 
inhibits cathepsin S, K, L and B. 
Cystatin-1 reduced the frequency of B cells in the CpG-activated group (Figure 
20A; n = 3; P < 0.05) but not in anti-IgM + IL-4 activated cells (Figure 20A; n = 3;). 
Cystatin-1 also reduced the frequency of CLIP+ B cells in CpG-activated cells (Figure 
20B; n = 3; P < 0.05), while it had no effect on BCR activation (Figure 20B; n = 3). 
Cystatin-1 inhibited the cell surface expression of CLIP on B cells in anti-IgM + IL-4 
activated cells, but not in CpG-activated splenocytes (Figure 20C; n = 3; P < 0.05). The 
surface expression of MHC-II on the B cells is unaltered in either of the activation 
groups with Cystatin-1 treatment (Figure 20D; n = 3). Cystatin-1 increased B cell 
surface expression of CD74 (MFI) in the anti-IgM + IL-4 activated group (Figure 20E: n 
= 3; P < 0.05), while it had no effect on B cell surface expression of CD74 (MFI) in the 
CpG-activated group (Figure 20E: n = 3). 
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Figure 20: Cathepsin Inhibitor 1 (Cystatin-1) reduces CLIP+ B cells. Panel A shows 
that Cystatin-1 reduces the frequency of B cells in the CpG-activated group, but not in 
anti-IgM + IL-4 stimulated group (n = 3; P < 0.05). Panel B shows that Cystatin-1 has a 
significant effect on the number of CLIP+ B cells in CpG stimulation, but not in BCR 
activation (n = 3; P < 0.05). Panel C shows that cell surface CLIP expression upon BCR 
activation is reduced with Cystatin-1 (n = 3; P < 0.05), while cystatin-1 had no effect on 
the level of cell surface CLIP in CpG-activated B cells. Panel D shows that Cystatin-1 
did not inhibit the surface MHC-II expression in either of the stimulations (n = 3). Figure 
E shows that Cystatin-1 significantly increases CD74 surface expression on B cells in 
anti-IgM + IL-4 activated splenocytes (n = 3; P < 0.05), while it had no effect on the 
CpG-activated group (n = 3). P values were calculated using Student’s t-test on 
GraphPad Prism. 
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Brefeldin A inhibits CLIP expression in vitro 
 Cell surface CD74, when bound by MIF, is proteolytically cleaved by the signal 
peptide peptidase-like 2a (SPPL2a) protease (Schroder and Saftig, 2016). The 
intracellular domain of CD74 (ICD) that gets cleaved at the membrane plays an 
important role in B cell differentiation and activation of NF-κB and activation of an 
inflammation pathway via its translocation to the nucleus (Matza et al., 2002a). In this 
experiment we used brefeldin A (BFA) an antibiotic. Splenocytes were activated with 
either CpG or with anti-IgM + IL-4 along with BFA at a concentration of 2.5µg/mL and 
incubated for 48 hours. We stained to assess markers for B cells, surface expression of 
CLIP, and MHC-II on the B cell subset. We observed that CpG-activated B cells were 
very sensitive to BFA treatment, with over half of B cells undergoing BFA-mediated cell 
death (Figure 21A; n = 3; P < 0.05), while in the anti-IgM + IL-4 activated group, the 
frequency of B cells did not change with BFA treatment (Figure 21A; n = 3). BFA 
strongly reduced the frequency of CLIP+ B cells in both the CpG and anti-IgM + IL-4 
activated cell cultures, (Figure 21B; n = 3; P < 0.05). The mean surface expression of 
CLIP per B cell went down in both stimulation groups (Figure 21C; n = 3; P < 0.05). 
The MHC-II surface expression in CpG-activated cells was reduced significantly while 
in anti-IgM + IL-4 activated cells it increased when treated with BFA (Figure 21D; n = 
3; P < 0.05). BFA significantly increased B cell surface CD74 (MFI) in anti-IgM + IL-4 
activated and CpG-activated splenocytes (Figure 21E: n = 3; P < 0.05). 
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Figure 21: BFA reduces CLIP+ B cells and surface CLIP. Panel A shows that the 
frequency of CpG-activated cells was reduced by half (n = 3; P < 0.05), when exposed to 
BFA, while there was no change in the frequency of anti-IgM + IL-4 activated 
splenocytes (n = 3). Panel B shows that the frequency of CLIP+ B cells was reduced in 
both CpG activated and anti-IgM+IL-4 stimulated cells (n = 3; P < 0.05). Panel C shows 
that CLIP (MFI) was significantly reduced in both CpG-activated as well as in anti-IgM 
+ IL-4 stimulated B cells with BFA treatment (n = 3; P < 0.05). Panel D shows that BFA 
reduced MHC-II expression on CpG-activated B cells, while it upregulated MHC-II on 
anti-IgM + IL-4 activated B cells (n = 3; P < 0.05). Panel E shows that BFA significantly 
increased CD74 surface expression on B cells in anti-IgM + IL-4 activated splenocytes 
and also in the CpG-activated group (n = 3; P < 0.05). P values were calculated using 
Student’s t-test on GraphPad Prism. 
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CLIP expression in MIF-KO B cells in vivo 
 In our preliminary experiment we compared the expression of CLIP on the 
surface of B cells in spleens of MIF-knockout (KO) mice that were generated on the 
C57BL/6 background to that of the C57BL/6 wild type. This experiment was done with 
the help of our colleagues in Dr. Richard Bucala’s group at Yale University, School of 
Medicine. We injected CpG dissolved in saline via the intraperitoneal route at 1 mg/kg 
of body mass of the animals into MIF-KO animals (n=2) and age matched C57BL/6 wild 
type control mice (n=3). At 48 hours post injection, the animals were sacrificed and the 
spleens were processed into single cell suspensions, free of red blood cells, and were 
stained for markers of B cells, MHC-II and CLIP.  
The data shows that MIF-KO animals had less B cells than wild type and CpG 
increased the frequency of B cells in wild type but not in MIF-KO animals (Figure 22A). 
CpG increased the frequency of CLIP+ B cells in wild type but not in MIF-KO (Figure 
22B). CpG increased the expression of CLIP (MFI) on the B cell surface in wild type but 
not in MIF-KO mice (Figure 22C). MIF-KO animals had a higher level of MHC-II 
surface expression on the B cells than in the wild type animals and CpG did not affect 
the expression of MHC-II in either of the mouse strains (Figure 22D). Even though we 
did not have enough animals to calculate statistical significance, these data show a trend 
that MIF is an important negative regulator of antigenic peptide presentation. 
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Figure 22: MIF-KO spleens have higher CLIP in vivo. Panel A preliminary data show 
that intraperitoneal injection of CpG into MIF-KO (n=2) animals did not increase the 
frequency of B cells as observed in C57BL/6 (BL6) wild type mice (n=3). In addition, 
the frequency of B cells in MIF-KO mice started off lower than in wild type animals. 
Panel B shows that MIF-KO mice started off with a high frequency of CLIP+ B cells, 
comparable to the wild type mice, and did not increase with CpG, unlike in the wild type 
animals. Panel C shows that the surface expression of CLIP on B cells in the MIF-KO 
animals was similar to the expression on the B cells from BL6 wild type mice, and while 
BL6 B cell surface CLIP expression went up with CpG there was no change in the CLIP 
expression on the B cells from MIF-KO animals. Panel D shows that MIF-KO animals 
started off with higher MHC-II expression when compared to that of BL6 wild type and 
it does not increase with CpG treatment. This was a preliminary experiment with fewer 
animals in each group and statistical analysis was not performed due to lower animal 
numbers. 
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The impact of MIF on B cell numbers, cell surface CLIP and cell surface MHC-II
 CD74 is the cell surface receptor for MIF. ISO-1 (4,5-Dihydro-3-(4-
hydroxyphenyl)-5-isoxazoleacetic acid methyl ester), is a cell permeable MIF antagonist 
that binds to the catalytic domain of MIF, thereby inhibiting its activity.  In this 
experiment, splenocytes isolated from C57BL/6 mice were cultured for 48 hours 
stimulated with either CpG or anti-IgM+IL-4 along with ISO-1 (concentration of 
40µg/mL) and the cells were later stained for B cell markers and CLIP, along with 
MHC-II expression and CD74. We predicted that ISO-1 would block the autocrine 
release of MIF from B cells upon CpG activation or anti-IgM + IL-4 stimulation. 
ISO-1 reduced the number of B cells in anti-IgM+IL-4 activated splenocytes 
(Figure 23A; n = 3; P < 0.05), while it did not change the total B cell frequency in the 
CpG-activated group. ISO-1 strongly inhibited the CLIP+ B cell frequency in CpG-
activated as well as in anti-IgM+IL-4 activated cells (Figure 23B; n = 3; P < 0.05). ISO-
1 strongly inhibited the expression of CLIP on the B cell surface in both CpG-activated 
and anti-IgM + IL-4 activated cells (Figure 23C; n = 3; P < 0.05). ISO-1 also reduced 
MHC-II expression in CpG-activated cells, likely indicating that the loss of CLIP in 
these cells was due to reduction in MHC-II translocation to the cell surface; while in 
anti-IgM + IL-4 activated cells, ISO-1 did not affect MHC-II expression (Figure 23D; n 
= 3; P < 0.05). ISO-1 increased B cell surface CD74 (MFI) in the anti-IgM + IL-4 
activated group (Figure 23E: n = 3; P < 0.05), while it had no effect on B cell surface 
CD74 (MFI) in the CpG-activated group (Figure 23E: n = 3). 
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Figure 23: ISO-1 regulates CLIP expression in vitro. Panel A shows that anti-IgM + IL-
4 activated splenocytes treated with ISO-1 display a reduced B cell frequency (n = 3; P < 
0.05), while there was no change in the frequency of B cells in CpG-activated cells. 
Panel B shows that ISO-1 reduced the number of CLIP+ B cells in both CpG and anti-
IgM + IL-4 activated splenocytes. Panel C shows that splenocytes activated with CpG or 
anti-IgM + IL-4 when treated with ISO-1 had reduced cell surface CLIP expression on B 
cells (n = 3; P < 0.05). Panel D shows that ISO-1 reduced MHC-II on B cells in CpG-
activated splenocytes, while there was no change in the anti-IgM + IL-4 activated group 
(n = 3; P <0.05). Panel E shows that ISO-1 significantly increased CD74 surface 
expression on B cells in anti-IgM + IL-4 activated splenocytes (n = 3; P < 0.05), while it 
had no effect on the CpG-activated group (n = 3). P values were calculated using 
Student’s t-test on GraphPad Prism. 
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MIF-098 inhibitor reduces CLIP expression 
 ISO-1 is a weak inhibitor of MIF so we repeated the same experiment with a 
strong antagonist of MIF, called MIF-098, generously provided by Dr. Richard Bucala. 
In this in vitro experiment, we activated C57BL/6 splenocytes with CpG, LPS, or anti-
IgM+IL-4 along with the MIF antagonist MIF-098 added at a concentration of 40 µg/mL 
for 48 hours, and then stained for CLIP, CD19, and MCH-II. Splenocytes have been 
found to be very sensitive to MIF-098. MIF-098 strongly reduced the frequency of 
CLIP+ B cells (Figure 24; n = 3; P < 0.05) and CLIP expression on the surface of B cells 
(Figure 24; n = 3; P < 0.05) under all the three stimulation conditions (CpG, LPS, anti-
IgM + IL-4). MIF-098 significantly increased the MHC-II surface expression (Figure 
24A, 24B, 24C; n = 3; P < 0.05) on the remaining B cells. 
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Figure 24: MIF-098 inhibits surface CLIP expression and CLIP+ B cell frequency. In 
Panel A, CpG-activated splenocytes when exposed to MIF-098 for 48 hours, had 
significantly reduced in CLIP+ B cells and CLIP (MFI), and increased MHC-II (MFI) (n 
= 3; P < 0.05). Panel B shows CLIP+ B cell suppression in the LPS-activated 
splenocytes treated with MIF-098. In addition, there was a significant reduction in CLIP 
(MFI) on B cells along with an increase in MHC-II (MFI) (n = 3; P < 0.05). Panel C 
shows that the 48 hour treatment with MIF-098 in vitro obliterated CLIP+ B cells and 
reduced the CLIP per B cell in the surviving cells, while increasing the MHC-II (MFI) (n 
= 3; P < 0.05) in anti-IgM + IL-4 activated splenocytes. P values were calculated using 
Student’s t-test on GraphPad Prism. 
 
  69 
MIF-098 facilitates antigenic peptide loading 
 As MIF-098 inhibits surface expression of CLIP on the B cell and CLIP+ B cell 
frequency, we addressed the possibility that MIF-098 treatment would facilitate 
antigenic peptide loading into the groove of MHC-II. For this experiment we activated 
splenocytes from C57BL/6 mice in vitro with either TLR9 agonist, TLR4 agonist or with 
BCR activation by anti-IgM + IL-4 treatment and incubated them for 48 hours with 
MIF-098 and biotinylated APi1702 peptide, a peptide with high affinity for MHC-II. 
The cells were stained for CLIP, and with fluorescein-conjugated streptavidin to detect 
the surface expression of APi1702. MIF-098 increased the ratio of APi1702 peptide 
loading to CLIP by nine-fold in CpG-activated cells (Figure 25A; n = 3; P < 0.05). LPS-
activated B cells treated with MIF-098 showed a seven-fold increase in the level of 
APi1702 peptide relative to the amount of CLIP loaded into the groove of MHC-II on 
the B cells (Figure 25B; n = 3; P < 0.05).  In anti-IgM + IL-4 stimulated splenocytes, the 
MIF-098 facilitated an increase in the peptide loading into the MHC-II groove by over 
fifteen fold, when compared to the control group (Figure 25C; n = 3; P < 0.05).  
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Figure 25: MIF-098 increases antigenic peptide loading. Panel A shows that in CpG-
activated splenocytes incubated with APi1702, this competitive binding peptide was 
loaded into the MHC-II at a higher efficiency when treated with MIF-098 than under 
control conditions (n = 3; P < 0.05). Panel B shows that in LPS-activated splenocytes 
incubated with APi1702 and MIF-098 there was a seven-fold increase in peptide loading 
(n = 3; P < 0.05). Panel C shows that in BCR activation, MIF-098 treatment significantly 
increased the APi1702 peptide loading efficiency into the MHC-II by fifteen-fold 
compared to control (n = 3; P < 0.05). P values were calculated using Student’s t-test on 
GraphPad Prism. 
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In vivo B6.lpr mice have high CLIP expression 
 B6.lpr mice have a mutation in the gene that encodes the Fas molecule and these 
mice exhibit the symptoms of systemic autoimmunity.  In this experiment, we examined 
the level of CLIP per B cell and the frequency of CLIP+ B cells, compared to BL6 wild 
type mice. For these in vivo experiments, B6.lpr mice were injected, via the 
intraperitoneal route, with CpG (n = 3) at 1mg/kg body weight. We also injected 
C57BL/6 mice (BL6) (n = 3) with CpG at the same concentration. At 72 hours post-
injection, the animals were sacrificed along with respective age-matched controls (n = 
3). The spleens were processed into single cell suspensions and stained for B cell, CLIP, 
and MHC-II expression.   
B6.lpr mice had fewer B cells when compared to the BL6 wild type mice and 
CpG activation did not increase the B cell frequency in these animals (Figure 26A; n = 
3). There was no significant increase in CLIP+ B cells in B6.lpr mice when compared to 
BL6 wild types (Figure 26B; n = 3). B6.lpr mice started off with higher CLIP (MFI) per 
B cell than the BL6 wild type mice (not statistically significant (ns)) and unlike BL6 
mice where the CLIP (MFI) increased with CpG injection, B6.lpr mice did not show any 
significant increase in the surface CLIP expression (Figure 26C; n = 3). There was no 
change in the surface expression of MHC-II on the B cells following CpG injection in 
both B6.lpr and wild type mice (Figure 26D; n = 3). 
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Figure 26: B6.lpr B cell surface CLIP expression in vivo. Panel A shows that in vivo 
CpG injection does not increase B cell frequency in B6.lpr, while in BL6 there was a 
significant increase in B cells (n = 3; P < 0.05). Panel B shows that CpG induced 
increase in CLIP+ B cells in BL (n = 3; P < 0.05), but not in B6.lpr mutant mice (n = 3). 
Panel C shows that B6.lpr mice tend to start off with higher CLIP (MFI) in B cells and 
CpG does not change (n = 3) the expression but in BL6 mice CpG significantly 
increased CLIP (MFI) on B cells (n = 3; P < 0.05). Panel D shows there was no change 
in MHC-II (MFI) in either of the mice strains injected with CpG (n = 3). P values were 
calculated using Student’s t-test on GraphPad Prism. 
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Antigenic peptide presentation by B cells from B6.lpr mice in vitro 
Because B6.lpr mice constitutively express higher levels of B cell surface CLIP 
than BL6 mice, we performed an in vitro experiment to determine the antigenic peptide 
loading ability and capability of peptide antigen presentation by MHC-II in B cells from 
these animals. For this experiment splenocytes from B6.lpr mice were activated with 
either CpG or LPS, at a concentration of 5µg/mL, or with anti-IgM + IL-4, at a 
concentration of 10µg/mL and 5ng/mL, respectively. Cells were treated for 48 hours 
with HCQ or rapamycin at a concentration of 10µM, along, with the biotinylated 
competitive binding peptide APi1702 at a final concentration of 5µg/mL. The cells were 
then stained for B cells, CLIP, and MHC-II on the B cell surface, followed by a second 
incubation with streptavidin to identify the surface bound APi1702 peptide in the groove 
of MHC-II.  
In CpG-activated splenocytes, HCQ significantly reduced the ratio of APi1702 to 
CLIP on the B cell surface (n = 3; P < 0.05), while rapamycin treatment did not change 
the ratio of APi1702 to CLIP on the B cell surface (Figure 27A; n = 3). Rapamycin 
increased the ratio of LPS-activated lpr cell surface APi1702 to CLIP by over fifteen-
fold, while HCQ reduced the APi1702 surface expression on B cells (Figure 27B; n = 3; 
P < 0.05).  In anti-IgM + IL-4 activated lpr splenocytes, rapamycin treatment resulted in 
a fifteen-fold increase in the APi1702 peptide presentation by B cells when compared to 
the control, while HCQ significantly reduced peptide presentation by the B cells (Figure 
27C; n = 3; P < 0.05).  
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Figure 27: B6.lpr in vitro antigenic peptide presentation by B cells. Panel A shows that 
in B6.lpr splenocytes activated with CpG and treated with HCQ or rapamycin along with 
APi1702, HCQ reduces the APi1702/CLIP ratio (n = 3; P < 0.05) while rapamycin has 
no effect. Panel B shows that rapamycin increases the surface expression of 
APi1702/CLIP ratio by fifteen fold compared to control while HCQ reduces the 
competitive peptide surface expression (n = 3; P < 0.05). Panel C indicates that in anti-
IgM + IL-4 activated splenocytes rapamycin treatment increases B cell surface 
expression of APi1702 just as with LPS activation and HCQ significantly reduces 
APi1702 by inhibiting autophagy (n = 3; P < 0.05). Statistical significance was evaluated 
by one-way ANOVA using GraphPad Prism. 
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6-AN and PS-341 reduce CLIP expression on cancer cells 
 CLIP in the groove of the MHC-II peptide-binding site inhibits cells death 
(Tobin, 2013). In this in vitro experiment we evaluated the possibility that induction of 
CMA will cause the loss of CLIP on the surface of cancer cells. Daudi and Raji human 
Burkitt lymphoma cells were treated with either 6-AN, at a concentration of 140 µM, or 
with PS-341, at 100 nM for 48 hours and then stained for CLIP on the cell surface. 6-AN 
significantly reduced the expression of CLIP in both Raji and Daudi cell lines without 
affecting the MHC-II surface expression (Figure 28; n = 3; P < 0.05). PS-341 was toxic 
to Raji cells (data not shown) and it reduced the level of cell surface CLIP in both Raji 
and Daudi cells, without affecting the MHC-II cell surface expression (Figure 28; n = 3; 
P < 0.05), indicating that these two drugs may increase the immunogenicity of the two 
cell lines for recognition by CD4+ T cells. 
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Figure 28: 6-AN and PS-341 reduce CLIP on surface of cancer cells in vitro. Panel A 
shows that 6-AN and PS-341 inhibited the expression of cell surface CLIP on the Daudi 
cell lines when incubated with these drugs for 48 hours (n = 3; P < 0.05), without 
reducing MHC-II surface expression. Panel B shows that 48 hours of treatment with 6-
AN or PS-341 reduced cell surface CLIP expression on Raji cells without affecting the 
level of MHC-II expression (n = 3; P < 0.05). Statistical significance was evaluated by 
one-way ANOVA using GraphPad Prism.  
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CHAPTER IV 
CONCLUSIONS 
 
The immune system functions to protect us from harm, and as such, is required to 
distinguish pathogenic invaders or harmful injury from harmless microbes or self-
antigens.   However, with every exposure to pathogens, the battle to control infectious 
disease is accompanied by the risk of autoimmunity, without strict controls to distinguish 
what is “self” from what is not. Although the immune system has historically been 
considered a system of “self versus non-self discrimination,” the recent discovery of 
cells that actively suppress antigen-specific responses, the regulatory networks 
(including myeloid suppressor cells as well as T and B regulatory cells that can help 
maintain self tolerance) suggest that, in fact, the immune system readily recognizes self 
and thus needs to be highly capable of suppressing self reactivity to avoid blatant 
autoimmunity.  
In the present thesis, our hypothesis was that CD74, and control over its 
processing into CLIP and cell surface CLIP presentation, are regulated by 
macroautophagy and CMA, and as such, are important in discriminating between “self” 
and “non-self” antigen presentation by B cells.  Furthermore, these processes regulate 
the expansion and survival of distinct B cell subsets that, in turn, may promote 
regulatory versus non-regulatory T cells. Toward that end, we examined (1) the 
contributions of macroautophagy to B cell survival, proliferation, cell surface CLIP 
expression, B cell subset selection, and antigenic peptide presentation; (2) the 
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mechanisms required to process CD74 and generate CLIP on activated B cells, including 
those mechanisms involving MIF binding to CD74 and the regulation that facilitates 
antigenic peptides loading into MHC-II on B cells; and (3) how the regulation of cell 
surface CLIP expression affects the potential for autoimmune disease and cancers. 
 
Macroautophagy: regulation of B cell survival, proliferation, cell surface CLIP 
expression, B cell subset selection, and antigenic peptide presentation  
Our previous work demonstrated that TLR activation, resulting in the 
proliferative expansion of naïve B cells, results in increased cell surface CLIP loaded 
into MHC-II on the responding, TLR-activated B cells (Newell et al., 2010). We 
reasoned that the TLR-driven response that results in proteolytic cleavage of CD74 into 
the CLIP peptide resulted from the absence of antigen-specific, BCR-driven activation 
of H-2M that would normally facilitate peptide exchange of CLIP for antigenic peptide. 
Thus, TLR activation would not activate H-2M and CLIP would remain in the groove of 
MHC-II in TLR-activated cells. However, to our surprise, we discovered that BCR 
engagement, along with IL4, resulted in even higher levels of cell surface CLIP (Tobin, 
2013), thereby likely limiting B cell MHC-II/antigen presentation to antigens recognized 
by the BCR as well as those processed and presented to CD4 T cells, with the remaining 
MHC-II molecules protected by the “placeholder” CLIP. Tobin et al. (Tobin, 2013) went 
on to show that while MHC-II engagement can result in the death of naïve B cells, CLIP 
in the groove of MHC-II is sufficient to prevent MHC-II-mediated cell death. Taken 
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together, these results illustrate that processing of CD74 and presentation of CLIP 
peptides may regulate presentation of antigenic peptides by B cells. 
Autophagy is a process whereby cytoplasmic contents are delivered for 
lysosomal degradation.  However, this pathway can also be used to deliver intracellular 
antigens for presentation to T cells and more recent evidence shows that autophagy also 
facilitates the processing of extracellular antigens via both MHC-II and MHC-I (Roche 
and Furuta, 2015). Furthermore, some antigens can be presented via MHC-II after 
intracellular processing, resulting in MHC-II presentation of the autophagic cargo 
(Schmid et al., 2007). Because TLR activation results in autophagy, we reasoned that 
cleavage of full length CD74 into CLIP might result from TLR-mediated autophagic 
events. To test the hypothesis that TLR-mediated increases in cell surface CLIP 
expression on B cells results from macroautophagy, we performed experiments in which 
we activated splenocytes with well-established TLR agonists - LPS or CpG, agonists for 
TLR 4, a cell surface receptor, and TLR 9, a lysosomal receptor, respectively.  We also 
included stimulation with anti-IgM and IL4 to compare the effects of TLR-mediated 
activation to antigen receptor engagement.  
In contrast to our prediction, we found that the well characterized inhibitor of 
mTOR, rapamycin, reduced the levels of cell surface CLIP under all of our activating 
conditions, thereby ruling out the possibility that the processing of CD74 into CLIP and 
the resulting cell surface expression of CLIP results from autophagy. However, to 
further substantiate this conclusion, we treated our cell cultures in each of our 
stimulating conditions with HCQ, an established inhibitor of autophagy.  In every case, 
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co-culture with HCQ increased the level of cell surface CLIP, thus supporting the 
interpretation that autophagy regulates the cell surface expression of CLIP in MHC-II 
once activated. One possible explanation for this result is that CLIP in the groove of cell 
surface MHC-II prevents the loading of exogenous peptide until physiological inhibition 
of mTOR occurs. Potential physiologic conditions that would inhibit mTOR include, but 
are not limited to, cellular starvation, metabolic stress, appropriate growth-controlling 
cytokines, such as IL-10 or TGF-β (Wu et al., 2016), or growth factor withdrawal of 
proliferation-promoting cytokines, such as IL-4. 
The downregulation of cell surface CLIP on B cells by inhibiting mTOR 
suggests that macroautophagy may prime B cells to present peptidic antigens. To 
determine if autophagy promotes peptidic antigen presentation by B cells stimulated via 
TLR ligands or via antigen receptor engagement, we utilized a synthetic peptide with a 
higher binding constant for the peptide binding groove of MHC-II than the CLIP 
peptide. We expected that if rapamycin “primed” the activated B cells for presentation of 
exogenous peptides, then the ratio of CLIP to the synthetic peptide would decrease with 
increasing concentrations of biotinylated peptide. We found that under all of the 
stimulation conditions, treatment with rapamycin facilitated an increase in antigenic 
peptide loading when compared to the control, while HCQ reduced the antigenic peptide 
loading.   
Under nutrient rich conditions, mTOR is known to be recruited to the surface of 
the lysosome where it forms a complex with “raptor”, creating the mTOR complex 1 
(mTORC1) that not only regulates lysosomal fusion with the autophagosome, but also 
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controls the lysosomal function by regulating the important lysosomal protein v-ATPase, 
which is known to regulate lysosomal acidification (Sancak et al., 2010; Zoncu et al., 
2011). So, based on this function, we predicted that active mTOR would inhibit 
exchange of peptides in the late endosome because of reduced lysosomal activity, as 
well as inhibition of lysosomal fusion with the early endosome. Rapamycin treatment 
inhibits mTOR, resulting in activation of v-ATPase to increase lysosomal acidity, thus 
enhancing the exchange of antigenic peptide with the CLIP in the MHC-II peptide-
binding groove of the late endosome, and thereby resulting in loss of B cell surface CLIP 
under all of the activation conditions (CpG, LPS, anti-IgM + IL-4). This prediction was 
also supported by our observations using HCQ, a well-known inhibitor of 
macroautophagy by neutralizing lysosomal acidity. HCQ suppressed the antigenic 
peptide exchange in the late endosome, and as a result, we observed more CLIP on the 
cell surface. 
Rapamycin treatment inhibits B cell proliferation with CpG activation, and also 
with BCR and IL-4 treatment. Marginal zone (MZ) and follicular (FO) B cells make up 
the majority of B cells in the spleen. MZ B cells are thought to carry out mostly T-
independent function, while FO B cells need T cell help for their function (Li et al., 
2001; Martin and Kearney, 2000). Several studies report that TLR agonists, like CpG, 
will activate MZ B more than FO B cells, while BCR engagement activates FO B cells 
more than MZ B cells (Lopes-Carvalho et al., 2005). Our observations show that 
rapamycin treatment inhibited the proliferation of B cells under all of the stimulation 
conditions, indicating that rapamycin can inhibit not only PI3K-dependent, mTOR 
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activation-induced proliferation by BCR engagement that mostly affects FO B cells, but 
also PI3K-independent, mTOR activation-induced proliferation, caused by TLR9 agonist 
binding to MZ B cells. 
Another important finding from our work is the effect of rapamycin we observed 
on B cell subsets in the peritoneum. The B cell subset composition of the peritoneum is 
different than that of secondary lymphoid organs such as the spleen. The spleen consists 
of predominantly B-2 B cells (FO and MZ B cells are B-2 B cells), while the B cell 
subpopulation of B-1 B cells are the major B cell residents of the peritoneum. B-1 B 
cells, just like MZ B cells, are T-cell independent and produce IgM antibody. So, we 
hypothesized that B-1 B cells should have similar sensitivity to rapamycin as the MZ B 
cells subset of B-2 cells. To our surprise, we observed that B-1 B cells are much more 
sensitive to rapamycin as indicated by significant decreases in the relative frequency of 
B-1 B cells, relative to B-2 B cells. Previous studies had established that FO B cells are 
less sensitive to TLR activation, when compared to MZ B cells, thus we reasoned that 
increased relative frequency of B-2 B cells in the peritoneum could be accounted for by 
MZ B cells. 
We evaluated the contribution of CMA to displacement of CLIP and the 
capability of antigen presentation in B cells. Because Dr. Janice Blum’s group had 
shown the importance of CMA in antigenic peptide presentation (Deffit and Blum, 
2015), we evaluated the level of cell surface CLIP expression using 6-AN, an activator 
of CMA, along with TLR9 or TLR4 stimulation, or with BCR engagement. Our results 
show that CLIP expression on the surface of the B cells is reduced with 6-AN under all 
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of the activation conditions, but surprisingly 6-AN also reduced cell surface MHC-II in 
both LPS and anti-IgM + IL-4 stimulated B cell subsets, while 6-AN did not affect the 
level of MHC-II expression on the CpG-activated group. These results indicate that CpG 
likely upregulates the LAMP-2C isoform, which according to Dr. Blum’s work inhibits 
CMA-mediated lysosomal degradation, while macroautophagy-mediated processes are 
unaffected. Thus, we believe that CpG overrides the 6-AN effect and continues to inhibit 
CMA, based on the observation that MHC-II expression is unchanged (Perez et al., 
2016). Because BCR cross-linking increases the expression of LAMP-2A, a translocator 
complex on the lysosome that increases the CMA process (Perez et al., 2016; Zhou et al., 
2005), we believe that both LPS activation as well as anti-IgM + IL-4 increase LAMP-
2A, resulting in CMA induction, and thereby results in a decrease in CLIP in the groove 
of MHC-II. Based on the reduction in MHC-II levels that we have observed in these 
activation groups, we suggest that CMA may not contribute to antigen presentation in 
our system. 
CD74 is an important component in the assembly of MHC-II molecules and their 
transport to the intracellular compartments and to the cell surface. In addition, CLIP, the 
proteolytic cleavage product of CD74, is essential in inhibiting binding of self-antigens 
in the cells. So, in our study, we evaluated how the loss of function of CD74 would 
affect the B cell response to activators and inhibitors of macroautophagy and CMA 
activators. Our initial evaluation of the immune cell sub-populations from the CD74 
deficient (CD74def) mice showed that these animals have fewer B cells in the spleen and 
in the peritoneum, and fewer CD4+ T cells compared to the BL6 WT mice. The cell 
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surface MHC-II expression on B cells from CD74def mice is significantly lower than in 
BL6 WT B cells. This finding is consistent with previous findings by other groups that 
have shown that CD74 is essential for B cell maturation and that lack of CD74 results in 
less MHC-II and less T cell selection due to the lack of variation in MHC-II bound 
peptide repertoire, thus affecting the positive selection of these cells in the thymus 
(Bikoff et al., 1993; Matza et al., 2002b).  
We activated splenocytes isolated from the CD74def mice with similar strategies 
used with BL6 WT splenocytes, including CpG, LPS and anti-IgM + IL-4. We also 
treated them with rapamycin, HCQ, and 6-AN. Because these animals have no CD74, 
there was no detectable CLIP on the surface of the B cells, so we evaluated how the 
expression of MHC-II changes on the B cells and the B cell frequency in all the 
activated groups treated with rapamycin or HCQ. Rapamycin treatment did not induce 
increased levels of MHC-II expression under any of the stimulation conditions, 
indicating that CD74 is essential for macroautophagy-induced exogenous peptide 
presentation. Because 6-AN treatment significantly increased MHC-II expression in 
TLR4- and TLR9-activated cells from the CD74def mice, the data suggest that these 
animals can readily utilize CMA for processing and presentation of antigenic peptides by 
B cells. The data also show that anti-IgM + IL-4 mediated activation results in the 
reduction of surface MHC-II on B cells and thus may indicate that exogenous antigens 
are limited to those recognized by the antigen receptor.  This is consistent with reports 
that CD74def mice are resistant to autoimmunity conditions (Sun et al., 2010). 
 
  85 
Mechanisms required for processing of CD74 and generating CLIP expression on 
activated B cells  
There are several very distinct functions of CD74.  Collectively, CD74 is a 
molecule involved in multiple processes in both innate and adaptive immune responses.  
First, CD74 is well characterized in APCs that also express MHC-II. Within the Golgi 
apparatus and endoplasmic reticulum of APCs, including B cells, CD74 is involved in 
the assembly of MHC-II molecules, and serves as a chaperone for MHC-II transport 
within the cell to the lysosome, and to the cell surface.   However, under conditions of 
inflammation, CD74 serves as the cell-surface receptor for MIF. As such, when MIF 
binds to CD74, the complex is internalized, and this event initiates downstream innate 
immune signaling, resulting from activation of the SPPL2a enzyme (Schneppenheim et 
al., 2013). The SPPL2a enzyme cleaves the CD74 N-terminal fragment (NTF) at 
cytoplasmic tail resulting in a 42-amino acid peptide which produces CD74 intracellular 
domain (ICD) and serves as a transcription factor that stimulates NF-κB activity (Matza 
et al., 2002a). Stimulation of NF-κB promotes inflammation associated with an innate 
immune response (Hayden et al., 2006). The remaining carboxy-terminal fragment 
resulting from SPPL2a cleavage of full-length CD74 contains the amino acid sequences 
that comprise MHC Class II Invariant Peptides (CLIPs), however the fate of the carboxy 
terminus is unknown. In addition to SPPL2a cleavage of CD74, there are 2 other distinct 
mechanisms by which CD74 can be cleaved into CLIPs: (1) When cell surface MHC-II 
molecules are internalized into phagolysosomes, containing cathepsins. Specifically 
cathepsin S in B cells, dendritic cells, and macrophages, cleaves MHC-II-associated 
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CD74 into CLIP (Riese et al., 1996).  Once cleaved, the CLIP peptide occupies the 
antigen-binding groove of MHC-II until HLA-DM (H-2M in mice) catalyzes the 
replacement of CLIP with antigenic peptides (Denzin and Cresswell, 1995). 
Replacement of CLIP allows the antigenic peptide to be recognized by a CD4+ T cell, 
the hallmark of the first-step in an antigen-specific adaptive immune response (Garcia 
and Teyton, 1998). (2) Within the proteasome, proteins, including CD74, are 
proteolytically cleaved into peptides containing 7-9 amino acids (Schrader et al., 2009). 
These peptides can be presented by MHC-II via cross presentation (Houde et al., 2003), 
and, as above, replacement of MHC-II-bound, cleaved CD74 peptides with antigenic 
peptide, and subsequent T cell recognition of the antigenic peptide in the peptide binding 
groove of MHC-II, initiates an adaptive immune response. Based on these potential 
mechanisms for generating CLIP peptides, we designed experiments to determine the 
impact of each of these mechanisms on generating cell surface CLIP peptides in the 
MHC binding groove on activated B cells, activated by either TLR or antigen receptor 
driven signals.  
We used PS-341, a well-known reversible inhibitor of the 26S proteasome. PS-
341 inhibited CLIP on the surface of B cells under all of our stimulation conditions 
(CpG, LPS and anti-IgM + IL-4) and the reduction in cell surface CLIP was 
accompanied by lower MHC-II expression on the surface of LPS and anti-IgM + IL-4 
activated cells, indicating that PS-341 may inhibit inflammatory signaling by stabilizing 
IκB-α, thus reducing the expression of NF-κB and inflammation, which in turn reduces 
CD74 synthesis and MHC-II expression (Sunwoo et al., 2001). An interesting 
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observation in CpG-activated splenocytes was that even though CLIP was reduced on 
the surface of the B cells, there was a striking increase in MHC-II cell surface 
expression, indicating that PS-341 likely does not regulate the CIITA-independent 
increase in expression of MHC-II that occurs in response to the MHC-II mRNA 
stabilization resulting from CpG activation (Kuchtey et al., 2003). 
Cathepsins are cysteine proteases involved in the proteolysis of the C-terminal 
portion of CD74 that is bound to MHC-II, thus leaving behind the peptide CLIP bound 
to the antigen-binding groove of MHC-II (Riese et al., 1998). In our results with 
Cystatin-1, we observed that, under conditions of CpG activation, the expression of 
CLIP on the B cell surface remain unaltered, indicating Cystatin-1 does not affect 
protein transcription or translation, but rather physically interacts with available 
cathepsins to inactivate them. In support of this supposition, other groups have found 
that TLR-mediated activation of cathepsins is controlled by MyD88-dependent and 
Myd88-independent induction of TNF-α and IL-1β, that positively regulate the mRNA 
expression of cathepsins B and S (Creasy and McCoy, 2011). In BCR cross-linking with 
anti-IgM + IL-4, Cystatin-1 acts synergistically in reducing the cathepsin activity, along 
with BCR engagement, that is known to transiently downregulate cathepsin S activity in 
B cells (Lankar et al., 2002). Cystatin-1 did not affect the expression of CD74 in CpG-
activated or in anti-IgM + IL-4 stimulated B cells, indicating that the activity of 
Cystatin-1 is not non-specific. 
The ICD produced by SPPL2a processing of NTF is known to induce 
inflammation by its translocation to the nucleus and induction of the NF-κB pathway. 
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Because there are no strong inhibitors of SPPL2a available, we used the fungal antibiotic 
Brefeldin A (BFA) to inhibit the translocation of the ICD to the nucleus, as reported in 
the literature (Matza et al., 2002a). BFA treatment resulted in the reduction of CLIP on 
the cell surface, without affecting the level of cell surface CD74. It is important to note 
that BFA has many non-specific effects, such as blocking protein transport from the 
Golgi and inhibition of cytokine production (Arioka et al., 1991; Schuerwegh et al., 
2001). Therefore, CLIP reduction due to BFA treatment could be the result of multiple 
effects of this inhibitor. 
 
Inhibition of MIF binding to CD74 reduces cell surface CLIP and facilitates 
antigenic peptides loading into MHC-II on B cells 
Intact CD74 also plays a key role in innate immunity via its actions as a cell 
surface receptor for MIF. In this context, MIF binding to CD74 leads to an association 
with CD44, as a signaling element, and to the internalization of the MIF/CD74 complex. 
Once MIF is bound and internalized, the CD74 molecule is cleaved by SPPL2a enzyme 
(Bucala and Shachar, 2015). 
To address the possibility that MIF-dependent processing of CD74 contributes to 
cell surface CLIP on B cells, we employed two inhibitors of MIF known as ISO-1 and 
MIF-098. For these experiments, we utilized our system of TLR activation with LPS or 
CpG and the use of antigen receptor engagement and IL-4, to determine the impact of 
MIF binding on the induction of cell surface CLIP on B cells. We found that B cells 
from the MIF-KO animals have constitutive levels of cell surface CLIP prior to the 
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addition of any of our stimuli. When we injected the MIF-KO mice in vivo with CpG 
there was no increase in the level of CLIP. We performed in vitro experiments using the 
MIF inhibitor ISO-1. CpG or anti-IgM + IL-4 activated splenocytes, when treated with 
ISO-1, displayed a reduction in cell surface CLIP on B cells, without an affect on the 
level of cell surface CD74. When we repeated the same in vitro experiment using MIF-
098, we observed a consistent and significant decrease in the cell surface CLIP 
expression and an increase in MHC-II expression on B cells under all three stimulation 
conditions, CpG, LPS, and anti-IgM + IL-4, indicating that MIF inhibition could lead to 
macroautophagy, and potentially antigenic peptide presentation. This interpretation was 
confirmed by using our competitive peptide-binding assay. MIF-098 treatment, under all 
the three stimulation conditions, increased the ratio of APi1702 to CLIP on the surface 
of B cells. This is an important finding because the contribution of MIF binding to 
antigenic peptide presentation has never been identified in B cells, although there has 
been studies indicating the loss of autophagy resulting in MIF secretion in innate 
immune cells (Lee et al., 2016). 
From these experiments, we learned that both ISO-1 and MIF-098 treatments 
decreased the amount of cell surface CLIP on B cells.  These results have several 
important implications.  Our data are the first to demonstrate the link between CD74’s 
contribution to an innate, inflammatory response and the expansion of B cells that 
express cell surface CLIP in MHC class II. Our results also demonstrate the importance 
of MIF inhibition in macroautophagy and antigenic peptide presentation in adaptive the 
immune system.   
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Regulation of cell surface CLIP expression: application to autoimmune disease and 
cancers  
Our work has demonstrated that the processing of CD74 into CLIP can be 
regulated specifically by mTOR inhibition-dependent autophagy, thereby resulting in 
reduced levels of CLIP and increased antigen presentation. Furthermore, by using a 
synthetic peptide with a high binding constant for cell surface MHC-II, we have shown 
that this mTOR inhibition-dependent reduction of CLIP selectively favors antigenic 
peptide presentation of exogenous peptides. In parallel with these studies, we have found 
that MIF inhibition reduces cell surface CLIP, thereby connecting the pro-inflammatory 
innate immune response with the antigen-specific adaptive immune response by creating 
and facilitating increased exogenous antigenic peptide loading into MHC-II.   
 In contrast, we have found that TLR activation that signals via the adaptor 
complex MyD88, and its selective activation of LAMP2C and CMA, controls 
endogenous, ie “self” antigen presentation.  This result has important implications for 
the development of new therapeutic targets for treating autoimmunity by limiting 
endogenous self-antigen presentation, or for cancer therapy, by increasing exogenous 
antigens on the tumor to promote anti-tumoral immune responses. Thus, there are at least 
two clinical implications of our findings as they relate to “self” versus “non-self” 
discrimination: the involvement of CLIP in self-antigen presentation and the potential 
involvement of CD74, and its processing into CLIP, in preventing anti-tumoral immune 
responses.  
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To confirm the clinical relevance of these findings, and based on the discovery 
that MyD88 signals result in increased endogenous peptide presentation of cell surface 
CLIP peptide, we examined the levels of cell surface CLIP on a well-established mouse 
model of autoimmune disease, the B6.lpr model. Strikingly similar to the MIF-KO 
splenocytes, the splenocytes from the B6.lpr animals constitutively expressed higher 
than wild type levels of CLIP on the B cell surface.  However, when either the B6.lpr 
cells or MIF-KO cells were stimulated with TLR agonists, the stimulation caused very 
minimal increases in the level of cell surface CLIP.  However, stimulation with antigen 
receptor caused a more significant increase in cell surface CLIP in the B6.lpr mice. Of 
importance, when the cells were treated with rapamycin, only stimulation with antigen 
receptor engagement and IL-4 were strongly capable of presenting exogenous antigen.  
The TLR9-activated cells from B6.lpr mice were non-responsive to the mTOR inhibitor 
rapamycin with respect to displaying exogenous antigenic peptides.  Thus, these data 
suggest that in this strain of autoimmune prone-animals, the B cells are limited to the 
presentation of endogenous, self-antigens. 
In the tumor cells, we observed that treatment with 6-AN reduces CLIP 
expression on the tumor cell surface, while the level of cell surface MHC-II expression 
was unaltered (Figure 28), suggesting that induction of CMA may increase the 
immunogenicity of these cancer cells, potentially making them more susceptible to the 
host immune anti-tumor response via the loss of CLIP on the tumor cell surface. Another 
significant finding from our studies is that in tumor cells that become resistant to the 
proteasomal inhibitors PS-341 or MG-132 proteasomal degradation drugs (Dowell et al., 
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2007; Hideshima et al., 2005) can still be targeted for an immune response because PS-
341 reduces CLIP, making the cancer cells good targets for MHC-II mediated extrinsic 
cell death, a potential promising immune therapy.  
Figure 29 illustrates our interpretation, and the potential importance, of our 
findings. Under normal/healthy conditions, when the B cell surface antigen receptor 
recognizes antigen, antigens presented are restricted to the presentation of antigens that 
have been recognized by the BCR, with a high number of the remaining peptides bound 
in the groove likely comprised of CLIP molecules. Once mTOR inhibition occurs, the 
antigen specific B cell presents predominantly exogenous antigens, Panel A.  Panel B 
illustrates that under autoimmune conditions, the lysosomal degradation of exogenous 
antigens and their loading into MHC-II is suppressed, with most of the antigen loaded 
into MHC-II coming from endogenous/cytosolic sources. Under these conditions the 
surface expression is predominantly endogenous antigens, including some CLIP 
peptides, suggesting that these B cells more prone to present cytosolic autoantigens. MIF 
binding to the surface CD74 can also potentiate self/cytosolic antigen presentation, while 
reducing exogenous antigen processing and presentation. Our data shows that blocking 
mTOR with rapamycin, and inducing mTOR-dependent autophagy, increases the 
exogenous antigen processing and presentation of exogenous peptides on the B cell 
surface, thus reducing the probability of presenting auto-antigens to T cells. In addition, 
by blocking MIF binding to CD74, our data suggest that we can induce autophagy and, 
thus promote better exogenous antigen presentation. 
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Figure 29: Autophagy induces exogenous antigen presentation. This figure illustrates 
activation of autophagy can improve exogenous antigen presentation in autoimmune 
conditions. Panel A shows BCR and antigen presentation on the B cells and effect of 
rapamycin. Panel B shows antigen presentation by a B cell in autoimmune conditions 
and effect of rapamycin. 
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Future studies 
For our future studies we will perform in vivo experiments with rapamycin and 
biotinylated APi1702 peptide in autoimmune disease models, including experiments in 
mouse models of experimental autoimmune encephalitis or in inflammatory bowel 
diseases. We will also utilize in vitro experiments to address the important question of 
whether rapamycin enables peptide exchange with CLIP in MHC-II on the B cell surface 
without the need for going though the endocytosis process. We will also plan to study 
the impact of rapamycin treatment on B cells as antigen presentation to CD4+ T cells 
and their activation. Finally, we will study the effect of PS-341 on immune cell 
regulation in in vivo mouse models of glioblastoma multiforme. 
Figure 29 Continued
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